1040:(FISH) is viewed as being the "gold standard" technique in identifying patients who would benefit from trastuzumab, but it is expensive and requires fluorescence microscopy and an image capture system. The main expense involved with CISH is in the purchase of FDA-approved kits, and as it is not a fluorescent technique it does not require specialist microscopy and slides may be kept permanently. Comparative studies of CISH and FISH have shown that these two techniques show excellent correlation. The lack of a separate chromosome 17 probe on the same section is an issue with regards to acceptance of CISH. As of June 2011 Roche has obtained FDA approval for the INFORM HER2 Dual ISH DNA Probe cocktail developed by
731:
improvement with nine weeks of treatment over no therapy. Because of the lack of direct head-to-head comparison in clinical trials, it is unknown whether a shorter duration of treatment may be just as effective (with fewer side effects) than the accepted practice of treatment for one year. Debate about treatment duration has become a relevant issue for many public health policy makers because administering trastuzumab for a year is very expensive. Consequently, some countries with a taxpayer-funded public health system, such as New
Zealand, chose to fund limited adjuvant therapy. However, subsequently New Zealand has revised its policy and now funds trastuzumab treatment for up to 12 months.
520:
684:) for the treatment of metastatic breast cancer. The overall hazard ratios (HR) for overall survival and progression free survival were 0.82 and 0.61, respectively. It was difficult to accurately ascertain the true impact of trastuzumab on survival, as in three of the seven trials, over half of the patients in the control arm were allowed to cross-over and receive trastuzumab after their cancer began to progress. Thus, this analysis likely underestimates the true survival benefit associated with trastuzumab treatment in this population.
49:
707:
with trastuzumab. It is surprising that although trastuzumab has great affinity for HER2 and high doses can be administered (because of its low toxicity), 70% of HER2+ patients do not respond to treatment. In fact resistance to the treatment develops rapidly, in virtually all patients. A mechanism of resistance involves failure to downregulate p27 (Kip1) as well as suppressing p27 translocation to the nucleus in breast cancer, enabling cdk2 to induce cell proliferation.
1044:. The DDISH (Dual-chromagen/Dual-hapten In-situ hybridization) cocktail uses both HER2 and Chromosome 17 hybridization probes for chromagenic visualization on the same tissue section. The detection can be achieved by using a combination of ultraView SISH(silver in-situ hybridization) and ultraView Red ISH for deposition of distinct chromgenic precipitates at the site of DNP or DIG labeled probes.
10289:
794:
4392:
4191:
2584:
2048:
1095:, beginning the first clinical trial with 15 women in 1992. By 1996, clinical trials had expanded to over 900 women, but due to pressure from advocates based on early success, Genentech worked with the FDA to begin a lottery system allowing 100 women each quarter access to the medication outside the trials. Herceptin was
878:
The HER2 pathway promotes cell growth and division when it is functioning normally; however, when it is overexpressed, cell growth accelerates beyond its normal limits. In some types of cancer, the pathway is exploited to promote rapid cell growth and proliferation and hence tumor formation. The EGF
706:
It is possible to determine the "erbB2 status" of a tumor, which can be used to predict efficacy of treatment with trastuzumab. If it is determined that a tumor is overexpressing the erbB2 oncogene and the patient has no significant pre-existing heart disease, then a patient is eligible for treatment
698:
The original studies of trastuzumab showed that it improved overall survival in late-stage (metastatic) HER2-positive breast cancer from 20.3 to 25.1 months. In early-stage HER2-positive breast cancer, it reduces the risk of cancer returning after surgery. The absolute reduction in the risk of cancer
730:
The optimal duration of add-on trastuzumab treatment after surgery for early breast cancer is unknown. One year of treatment is generally accepted based on clinical trial evidence that demonstrated the superiority of one-year treatment over none. However, a small
Finnish trial also showed similar
1250:
In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tuznue, intended for the treatment of breast and gastric cancer. The applicant for this medicinal product is
Prestige Biopharma Belgium BVBA. Tuznue is a biosimilar
1243:
adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product
Herwenda, intended for the treatment of HER2-positive breast and gastric cancer. The applicant for this medicinal product is Sandoz GmbH. Herwenda was approved for medical use in November
981:
both by induction of antiangiogenic factors and repression of proangiogenic factors. It is thought that a contribution to the unregulated growth observed in cancer could be due to proteolytic cleavage of HER2/neu that results in the release of the extracellular domain. One of the most relevant
1196:
In 2016, the investigational biosimilar MYL-1401O showed comparable efficacy and safety to the
Herceptin branded trastuzumab. Trastuzumab-dkst (Ogivri, Mylan GmbH) was approved in the United States in December 2017, to "treat people with breast cancer or gastric or gastroesophageal junction
1052:
One of the challenges in the treatment of breast cancer patients by herceptin is our understanding towards herceptin resistance. In the last decade, several assays have been performed to understand the mechanism of
Herceptin resistance with/without supplementary drugs. Recently, all this
1207:
Herzuma was approved for medical use in the
European Union in February 2018. Herzuma, a trastuzumab biosimilar, was approved in the United States in December 2018. The approval was based on comparisons of extensive structural and functional product characterization, animal data, human
972:
Trastuzumab binds to domain IV of the extracellular segment of the HER2/neu receptor. Monoclonal antibodies that bind to this region have been shown to reverse the phenotype of HER2/neu expressing tumor cells. Cells treated with trastuzumab undergo arrest during the G1 phase of the
1001:
Trastuzumab inhibits the effects of overexpression of HER2. If the breast cancer does not overexpress HER2, trastuzumab will have no beneficial effect (and may cause harm). Doctors use laboratory tests to discover whether HER2 is overexpressed. In the routine
907:(human epidermal growth factor receptor) protein, binds to human epidermal growth factor, and stimulates cell proliferation. In some cancers, notably certain types of breast cancer, HER2 is over-expressed and causes cancer cells to reproduce uncontrollably.
934:). ERBB2 is the preferred dimerization partner for the other family members and ERBB2 heterodimers signaling is stronger and longer acting compared to heterodimers between other ERBB members. It has been reported that Trastuzumab induces the formation of
699:
returning within three years was 9.5%, and the absolute reduction in the risk of death within 3 years was reduced by 3%. However, it increases serious heart problems by an absolute risk of 2.1%, though the problems may resolve if treatment is stopped.
4003:
702:
Trastuzumab has had a "major impact in the treatment of HER2-positive metastatic breast cancer." The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone.
1155:
distributors not through the usual general line wholesalers. By being forced to purchase through specialty pharmacies, hospitals lost rebates from the big wholesalers and the ability to negotiate cost-minus discounts with their wholesalers.
4208:
4703:
2021:
4212:
1018:
of formalin-fixed paraffin embedded tumor. Virtual karyotyping has the added advantage of assessing copy number changes throughout the genome, in addition to detecting HER-2 amplification (but not overexpression). Numerous
895:
pathway as well as the PI3 kinase/AKT pathway, which in turn activates the NF-κB pathway. In cancer cells the HER2 protein can be expressed up to 100 times more than in normal cells (2 million versus 20,000 per cell).
4733:
3815:
3529:
1106:
obtained regulatory approval to sell a biosimilar in 2014, but Roche contested the legality of the approval; that litigation ended in 2016, and Biocon and Mylan each introduced their own branded biosimilars.
3478:
2569:
3964:
3846:
129:
trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, trastuzumab-strf, Hercessi, Herzuma, Herwenda, Kanjinti, Ogivri, Ontruzant, Trastucip, Trazimera, Tuzucip, Zercepac
1936:
3987:
1208:
pharmacokinetic, clinical immunogenicity, and other clinical data demonstrating that
Herzuma is biosimilar to US Herceptin. Herzuma has been approved as a biosimilar, not as an interchangeable product.
4134:
4669:
1204:
Co., Ltd, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. Ontruzant is the first trastuzumab biosimilar to receive regulatory approval in Europe.
867:. Trastuzumab is a monoclonal antibody targeting HER2, inducing an immune-mediated response that causes internalization and recycling of HER2. It may also upregulate cell cycle inhibitors such as
695:
RR = 1.83) were seen in these trials as well. Two trials involving shorter term treatment with trastuzumab did not differ in efficacy from longer trials, but produced less cardiac toxicity.
1144:
Roche has changed the brand name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named
Herclon would cost approximately RS75,000 INR (
750:
One of the more serious complications of trastuzumab is its effect on the heart, although this is rare. In 2–7% of cases, trastuzumab is associated with cardiac dysfunction, which includes
4691:
3559:
2033:
3182:
Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. (February 2003). "Structure of the extracellular region of HER2 alone and in complex with the
Herceptin Fab".
3067:
Feldman AM, Koch WJ, Force TL (June 2007). "Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences".
3664:
Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. (December 1984). "The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen".
2650:
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. (October 2005). "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer".
283:
9566:
4176:
3045:
977:
so there is reduced proliferation. It has been suggested that trastuzumab does not alter HER-2 expression, but downregulates activation of AKT. In addition, trastuzumab suppresses
4573:
4543:
4513:
4483:
1764:
4271:
3782:
2875:
van Hasselt JG, Boekhout AH, Beijnen JH, Schellens JH, Huitema AD (July 2011). "Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity".
3233:
Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI (December 1984). "Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene".
722:
chemotherapy for the first-line treatment of people with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
9586:
777:
as well as focal adhesion kinases (FAK). These are all significant for the function and structure of cardiomyocytes. Trastuzumab can therefore lead to cardiac dysfunction.
4927:
4725:
1797:
1545:
1480:
1398:
1365:
1332:
1431:
9576:
7355:
4071:
7731:
3533:
946:
phosphorylation and EGFR/ERBB1 expression are both required for CDR formation. CDR formation requires activation of both the protein regulator of actin polymerization
3903:
3474:
2557:
1077:'s lab and the monoclonal antibody recognizing the oncogenic receptor by Mark Greene's lab also contributed to the establishment of HER2 targeted therapies. Dr.
3956:
3838:
914:(specifically EGF in this case) arrive at the cell membrane, and bind to the extracellular domain of the HER family of receptors. Those bound proteins then link (
3530:"Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully Automated Diagnostic Assay for HER2 Gene Status Determination in Breast Cancer Patients"
1924:
3284:
Albanell J, Codony J, Rovira A, Mellado B, Gascón P (2003). "Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4".
2966:
2815:
10339:
9561:
989:
Experiments in laboratory animals indicate that antibodies, including trastuzumab, when bound to a cell, induce immune cells to kill that cell, and that such
4142:
238:
4661:
4338:
2783:
8096:
3805:
2840:
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. (March 2002). "Cardiac dysfunction in the trastuzumab clinical trials experience".
1151:
On 16 September 2014, Genentech notified hospitals in the United States that, as of October, trastuzumab could only be purchased through their selected
590:
4789:
4094:
4606:
1863:
918:), activating the receptor. HER2 sends a signal from its intracellular domain, activating several different biochemical pathways. These include the
9331:
7406:
6358:
4920:
691:(HR) = 0.66) and disease-free survival (HR = 0.60). Increased risk of heart failure (RR = 5.11) and decline in left ventricular ejection fraction (
9270:
2135:
8447:
7639:
7348:
4377:
2752:
Metcalfe S, Evans J, Priest G (June 2007). "PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer".
3555:
1734:
1712:
899:
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell (molecules called
10230:
8372:
6421:
1236:
4651:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
4619:
Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
10314:
9954:
9867:
9812:
9766:
9711:
9446:
9386:
8387:
8317:
7876:
7474:
7416:
6416:
5361:
5346:
4859:
2070:
The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023)
990:
134:
9949:
9827:
9726:
9512:
9401:
9201:
9161:
8909:
8828:
8690:
8631:
8593:
8538:
8533:
8523:
8397:
8392:
8362:
8337:
8332:
8322:
8208:
8127:
8066:
7994:
7973:
7958:
7911:
7564:
1182:
4164:
3934:
3037:
10049:
9907:
9886:
9842:
9822:
9741:
9721:
9436:
9416:
9396:
9039:
9034:
8367:
8091:
7624:
7421:
4913:
4453:
4245:
3325:
Clynes RA, Towers TL, Presta LG, Ravetch JV (April 2000). "Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets".
1972:
4420:
3556:"Dual color dual hapten HER2 genotyping for breast biopsy specimens (DDISH): Concordance with fluorescence in situ hybridization (FISH)"
1620:
668:
Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the
10324:
9872:
9862:
9817:
9771:
9761:
9716:
9540:
9507:
9487:
9451:
9441:
9391:
9351:
8823:
8803:
8770:
8651:
8553:
8402:
7341:
4565:
4535:
4505:
4475:
4304:
1756:
1515:
1833:
1584:
10329:
9832:
9731:
9626:
9530:
9482:
9475:
9461:
9406:
9376:
8856:
8846:
8798:
8780:
8709:
8543:
8382:
8327:
4267:
1197:
adenocarcinoma whose tumors overexpress the HER-2 gene." Ogivri was approved for medical use in the European Union in December 2018.
70:
3774:
9571:
9261:
6767:
1299:
8866:
8583:
5919:
5562:
1789:
1537:
1472:
1423:
1390:
1357:
1324:
9671:
7851:
7534:
4059:
4036:
1902:
1653:
10309:
10249:
10199:
10170:
10117:
8604:
8471:
7299:
6968:
3301:
2002:
669:
645:
Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. Other severe side effects include
4692:"FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies"
1130:
Since October 2006, trastuzumab has been made available for Australian women and men with early-stage breast cancer via the
9928:
9924:
9920:
9916:
7469:
7453:
7188:
6351:
5055:
3907:
910:
HER2 is localized at the cell surface, and carries signals from outside the cell to the inside. Signaling compounds called
762:
is commonly undertaken during the trastuzumab treatment period. The decline in ejection fraction appears to be reversible.
4871:
891:; the binding of ligands (e.g. EGF etc.) to HER receptors is required to activate the pathway. The pathway initiates the
8197:
8116:
7983:
7900:
935:
3119:
1081:
subsequently worked on trastuzumab's development. A book about Dr. Slamon's work was made into a television film called
958:
regulator p140Cap, as we found that p140Cap overexpression led to cofilin deactivation and inhibition of CDR formation.
9912:
6825:
6752:
6657:
6033:
597:
171:
9601:
8720:
8280:
7891:
6682:
4768:
2959:
2808:
1178:
versions of trastuzumab after Roche/Genentech's patents expired in 2014 in Europe, and in 2019 in the United States.
1037:
969:(CDKs). Overexpression of HER2 sidesteps these checkpoints, causing cells to proliferate in an uncontrolled fashion.
836:
930:
pathway. Signals on these pathways promote cell proliferation and the growth of blood vessels to nourish the tumor (
7549:
7493:
7484:
7316:
5453:
4979:
3370:"A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer"
1457:
939:
927:
892:
2464:"HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways"
10123:
6344:
4326:
2779:
680:
The safety and efficacy of trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or
268:
152:
3839:"Mylan and Biocon finally win right to sell Herceptin biosim in India even as they have taken it to U.S. and EU"
965:—has checkpoints that keep cell division under control. Some of the proteins that control this cycle are called
10210:
10186:
9326:
8882:
8745:
6667:
1131:
10176:
6772:
4120:
1189:, and announced its readiness to export the drug to other countries in the Middle-East and Central Asia when
719:
739:
Some of the common side effects of trastuzumab are flu-like symptoms (such as fever, chills and mild pain),
10220:
8616:
8498:
8488:
6631:
5799:
4779:
4697:
4371:
4332:
4170:
2563:
2027:
1930:
1424:"Trazimera- trastuzumab-qyyp kit; Trazimera- trastuzumab-qyyp injection, powder, lyophilized, for solution"
818:
515:
448:
4598:
1855:
497:
9591:
5980:
4956:
3642:
1676:"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)"
1325:"Kanjinti- trastuzumab-anns injection, powder, lyophilized, for solution; Kanjinti- trastuzumab-anns kit"
1074:
4905:
3507:
10279:
10205:
8031:
6410:
6105:
5954:
5703:
5205:
687:
In early-stage HER2-positive breast cancer, trastuzumab-containing regimens improved overall survival (
4365:
2991:
Bange J, Zwick E, Ullrich A (May 2001). "Molecular targets for breast cancer therapy and prevention".
10113:
6875:
5430:
5296:
5009:
4447:
4414:
4298:
4239:
3717:"Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen"
2703:
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. (February 2006).
2389:
Nahta R, Esteva FJ (November 2003). "HER-2-targeted therapy: lessons learned and future directions".
2065:
1966:
1827:
1742:
1704:
1675:
1614:
1240:
1020:
809:
17:
401:
80:
10334:
8297:
8213:
8132:
7999:
7916:
5440:
4966:
3583:"Herceptin resistance database for understanding mechanism of resistance in breast cancer patients"
1083:
966:
751:
4894:
4268:"Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar. Nov 2017"
9897:
7644:
7519:
7304:
7271:
7212:
7163:
7078:
6702:
4936:
2508:
Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, et al. (February 2004).
1260:
1041:
1031:
1023:-based methodologies have also been described in the literature. It is also possible to estimate
900:
631:
208:
114:
4807:"The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer"
3928:
Australian Government, Dept of Health and Ageing "Listing of Herceptin on PBS", 1 October 2006.
1790:"Herceptin- trastuzumab kit Herceptin- trastuzumab injection, powder, lyophilized, for solution"
1576:
10181:
9797:
9701:
9321:
8740:
7726:
7364:
7242:
7232:
7202:
6993:
6938:
6865:
6855:
6732:
5808:
5291:
5020:
3930:
2301:
Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. (April 2012).
2214:
Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. (April 2012).
1391:"Ontruzant- trastuzumab injection, powder, lyophilized, for solution; Ontruzant- ontruzant kit"
1268:
1190:
1134:. This is estimated to cost the country over A$ 470 million for 4–5 years supply of the drug.
639:
627:
219:
4442:
4234:
2093:
Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, et al. (June 2014).
1961:
10255:
8452:
7736:
7375:
7217:
7206:
7168:
7058:
7043:
6973:
6953:
6948:
6727:
6481:
5366:
5306:
5276:
5179:
5015:
4634:
4409:
3419:"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups"
1609:
1507:
1473:"Herzuma- trastuzumab kit; Herzuma- trastuzumab injection, powder, lyophilized, for solution"
1264:
1247:
Trastuzumab-strf (Hercessi) was approved for medical use in the United States in April 2024.
1011:
986:. Trastuzumab has been shown to inhibit HER2/neu ectodomain cleavage in breast cancer cells.
31:
4293:
2601:
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. (October 2005).
2094:
1200:
In November 2017, the European Commission approved Ontruzant, a biosimilar-trastuzumab from
375:
10195:
9581:
8513:
8462:
7068:
6928:
6697:
6662:
5221:
5116:
4953:
3728:
3673:
3594:
3430:
3242:
3191:
1822:
1538:"Ogivri- trastuzumab kit; Ogivri- trastuzumab injection, powder, lyophilized, for solution"
1358:"Ogivri- trastuzumab kit; Ogivri- trastuzumab injection, powder, lyophilized, for solution"
1141:
in India to make an affordable version of this cancer drug available to the Indian market.
1007:
635:
457:
348:
231:
4209:"FDA approves Ogivri, first biosimilar for certain breast, stomach cancers. December 2017"
3417:
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. (April 2012).
954:, mediated by EGFR/ERBB1. Furthermore, this latter event may be inhibited by the negative
8:
10319:
9336:
8750:
7183:
7153:
7148:
7133:
6963:
6810:
6762:
6722:
6367:
6074:
5341:
5331:
5151:
1003:
615:
366:
63:
4805:
Dent S, Verma S, Latreille J, Rayson D, Clemons M, Mackey J, et al. (August 2009).
3732:
3677:
3598:
3434:
3246:
3195:
2186:
2161:
519:
9014:
7367:
6905:
6456:
5729:
5266:
4831:
4806:
3885:
3810:
3697:
3615:
3582:
3451:
3418:
3350:
3266:
3215:
3092:
3016:
2936:
2919:
2900:
2734:
2685:
2632:
2539:
2327:
2302:
2266:
Hudis CA (July 2007). "Trastuzumab--mechanism of action and use in clinical practice".
2240:
2215:
2122:
1925:"FDA approves first biosimilar for the treatment of certain breast and stomach cancers"
1291:
1066:
1030:
There are two FDA-approved commercial kits available for HER2 IHC; Dako HercepTest and
650:
182:
3751:
3716:
3394:
3369:
982:
proteins that trastuzumab activates is the tumor suppressor p27 (kip1), also known as
9641:
6792:
6611:
5406:
4863:
4836:
4764:
4114:
3995:
3877:
3756:
3689:
3620:
3456:
3399:
3342:
3307:
3297:
3258:
3207:
3164:
3084:
3008:
2941:
2892:
2857:
2761:
2726:
2677:
2624:
2531:
2485:
2439:
2398:
2371:
2367:
2332:
2283:
2245:
2191:
2127:
1998:
1015:
804:
295:
7333:
3354:
3096:
2904:
2738:
2689:
2543:
1185:. Iran also approved its own version of the monoclonal antibody in January 2016, as
48:
10059:
9191:
6336:
5246:
5088:
5083:
4826:
4818:
4026:
3889:
3869:
3746:
3736:
3701:
3681:
3610:
3602:
3446:
3438:
3389:
3381:
3334:
3289:
3270:
3250:
3219:
3199:
3154:
3076:
3020:
3000:
2931:
2884:
2849:
2716:
2667:
2659:
2636:
2614:
2558:"FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer"
2521:
2475:
2429:
2363:
2322:
2318:
2314:
2275:
2235:
2231:
2227:
2181:
2173:
2117:
2113:
2109:
2073:
1898:
1645:
1181:
In January 2015, BIOCAD announced the first trastuzumab biosimilar approved by the
1096:
774:
759:
715:
532:
330:
251:
144:
4726:"FDA grants regular approval to fam-trastuzumab deruxtecan-nxki for breast cancer"
3906:. Australian Government, Dept of Health and Ageing. 1 October 2006. Archived from
3288:. Advances in Experimental Medicine and Biology. Vol. 532. pp. 253–268.
773:
and the maintenance of cardiac function. NRG-1 activates the MAPK pathway and the
10293:
4031:
3293:
2705:"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer"
2603:"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer"
2351:
1201:
1171:
1152:
338:
4849:
1458:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761346Orig1s000lbl.pdf
10245:
10166:
10108:
9802:
9651:
9646:
8760:
8755:
7401:
7391:
7386:
7310:
7276:
6943:
6183:
6081:
6029:
5627:
4940:
4853:
3721:
Proceedings of the National Academy of Sciences of the United States of America
1232:
Trastucip and Tuzucip were approved for medical use in Australia in July 2022.
623:
3806:"Drug Is Shown to Shrink Tumors in Breast Cancer Characterized by Gene Defect"
2177:
1053:
information has been collected and compiled in form of a database HerceptinR.
10303:
9939:
9852:
9781:
9751:
9686:
9596:
9550:
9426:
9356:
9301:
9290:
8775:
8483:
8166:
8071:
7963:
7158:
7013:
6566:
6401:
6240:
6130:
6092:
6069:
6001:
5996:
5986:
5762:
5758:
5746:
5553:
5336:
5301:
5121:
5101:
4396:
4195:
3999:
3931:"Pharmaceutical Benefits Scheme (PBS) | Listing of Herceptin on the PBS"
3860:
Fleck LM (2006). "The costs of caring: Who pays? Who profits? Who panders?".
3111:
2649:
2588:
2354:(October 2003). "Ongoing adjuvant trials with trastuzumab in breast cancer".
2052:
1127:
Australia has negotiated a lower price of A$ 50,000 per course of treatment.
1078:
955:
915:
864:
770:
711:
692:
662:
646:
619:
508:
308:
3741:
3080:
769:(NRG-1), which is essential for the activation of cell survival pathways in
40:
10265:
10235:
9974:
9964:
9857:
9756:
9611:
9431:
9366:
9281:
8785:
8588:
8427:
8422:
8342:
8292:
8106:
7860:
7841:
7820:
7791:
7514:
7509:
7173:
7138:
7123:
7118:
7113:
7108:
7083:
7038:
7033:
7028:
7023:
7008:
6895:
6870:
6850:
6712:
6677:
6616:
6596:
6406:
6391:
6280:
6265:
6235:
6215:
6097:
6045:
6006:
5894:
5873:
5780:
5742:
5643:
5618:
5614:
5498:
5463:
5416:
5401:
5356:
5231:
5201:
5126:
4944:
4867:
4840:
4784:
4761:
Her-2: the making of Herceptin, a revolutionary treatment for breast cancer
3881:
3624:
3460:
3346:
3311:
3211:
3168:
3159:
3142:
3088:
3012:
2945:
2896:
2861:
2765:
2730:
2681:
2628:
2535:
2489:
2443:
2434:
2417:
2402:
2375:
2336:
2287:
2249:
2195:
2131:
1214:
Trazimera was approved for medical use in the European Union in July 2018.
1069:
at Genentech, Inc. in South San Francisco, CA. Earlier discovery about the
1062:
978:
931:
766:
688:
654:
246:
4135:"Biosimilar Matches Trastuzumab in Metastatic HER2-Positive Breast Cancer"
3873:
3760:
3693:
3403:
3368:
Jennings BA, Hadfield JE, Worsley SD, Girling A, Willis G (October 1997).
3262:
2853:
1229:
Zercepac was approved for medical use in the European Union in July 2020.
10225:
10191:
10089:
10079:
10074:
10064:
10014:
9837:
9736:
9497:
9411:
9341:
9236:
8999:
8964:
8914:
8877:
8813:
8695:
8626:
8578:
8568:
8563:
8558:
8442:
8437:
8432:
7810:
7711:
7679:
7674:
7669:
7664:
7654:
7614:
7579:
7281:
7255:
7250:
7222:
7193:
7128:
7103:
7093:
7063:
7053:
7018:
7003:
6988:
6978:
6958:
6933:
6918:
6890:
6840:
6835:
6830:
6815:
6805:
6782:
6777:
6747:
6692:
6636:
6626:
6601:
6591:
6586:
6581:
6556:
6531:
6521:
6516:
6511:
6501:
6486:
6471:
6466:
6451:
6446:
6436:
6431:
6426:
6396:
6310:
6290:
6285:
6275:
6255:
6230:
6225:
6208:
6156:
6146:
6141:
6136:
6038:
5965:
5935:
5930:
5925:
5909:
5899:
5879:
5754:
5750:
5738:
5734:
5663:
5567:
5513:
5508:
5473:
5411:
5396:
5386:
5381:
5376:
5371:
5351:
5316:
5271:
5251:
5241:
5196:
5161:
5141:
5097:
5060:
5048:
5043:
4989:
4935:
4822:
2888:
2721:
2704:
2663:
2619:
2602:
2526:
2509:
2279:
1211:
Kanjinti was approved for medical use in the European Union in May 2018.
1165:
215:
3442:
3385:
3203:
2672:
2480:
2463:
2078:
421:
10044:
10009:
10004:
9994:
9984:
9902:
9691:
9666:
9656:
9502:
9456:
9316:
9142:
9111:
9080:
9049:
8994:
8969:
8949:
8934:
8924:
8818:
8735:
8528:
8508:
8407:
8352:
8347:
8171:
8076:
8061:
7856:
7815:
7787:
7756:
7716:
7619:
7574:
7569:
7544:
7539:
7529:
7442:
7436:
7426:
7227:
7178:
7143:
7073:
7048:
6998:
6983:
6923:
6913:
6885:
6860:
6800:
6742:
6737:
6672:
6652:
6606:
6576:
6571:
6561:
6551:
6546:
6536:
6526:
6496:
6491:
6461:
6441:
6325:
6320:
6295:
6260:
6245:
6220:
6203:
6193:
6151:
6122:
6087:
6053:
5970:
5960:
5940:
5904:
5889:
5884:
5854:
5788:
5784:
5766:
5714:
5693:
5653:
5648:
5587:
5518:
5493:
5468:
5391:
5326:
5286:
5281:
5261:
5256:
5236:
5226:
5216:
5131:
5111:
5093:
5001:
1175:
974:
571:
432:
226:
124:
54:
3606:
2162:"Treating metastatic breast cancer: the evidence for targeted therapy"
10069:
10039:
10034:
10029:
10024:
10019:
9999:
9989:
9979:
9969:
9661:
9621:
9517:
9492:
9251:
9246:
9241:
9231:
9226:
9221:
9211:
9132:
9070:
9004:
8984:
8979:
8974:
8959:
8954:
8944:
8939:
8833:
8808:
8573:
8493:
8412:
8357:
8247:
8186:
8176:
8081:
7968:
7766:
7761:
7751:
7659:
7649:
7634:
7609:
7604:
7594:
7589:
7584:
7098:
7088:
6880:
6845:
6820:
6757:
6717:
6707:
6687:
6621:
6541:
6506:
6476:
6315:
6305:
6300:
6270:
6250:
6198:
6188:
6176:
6171:
6117:
6112:
6058:
5991:
5864:
5859:
5844:
5839:
5834:
5824:
5819:
5814:
5719:
5709:
5688:
5683:
5678:
5673:
5668:
5658:
5638:
5602:
5597:
5592:
5582:
5577:
5544:
5539:
5534:
5503:
5483:
5478:
5321:
5311:
5136:
4984:
3778:
3685:
3254:
2022:"Trastuzumab Product Approval Information - Licensing Action 9/25/98"
1088:
755:
681:
658:
386:
138:
85:
2702:
10240:
9959:
9616:
9216:
9206:
9186:
8929:
8919:
8266:
7746:
7689:
7599:
7559:
6376:
6065:
5829:
5633:
5572:
5528:
5488:
5458:
5211:
5075:
5071:
4996:
2874:
911:
904:
851:
744:
477:
412:
166:
102:
9121:
9090:
9059:
9023:
3338:
3004:
2418:"Overexpression of ErbB2 in cancer and ErbB2-targeting strategies"
1226:
Kanjinti was approved for medical use in Canada in February 2020.
1223:
Herzuma was approved for medical use in Canada in September 2019.
10215:
9636:
9101:
8503:
7464:
5169:
4395:
This article incorporates text from this source, which is in the
4194:
This article incorporates text from this source, which is in the
3581:
Ahmad S, Gupta S, Kumar R, Varshney GC, Raghava GP (March 2014).
2587:
This article incorporates text from this source, which is in the
2092:
2051:
This article incorporates text from this source, which is in the
1220:
Trazimera was approved for medical use in Canada in August 2019.
1186:
962:
951:
97:
4662:"FDA approves ado-trastuzumab emtansine for early breast cancer"
4593:
4591:
3988:"Swiss drugmaker Roche launches costliest cancer drugs in India"
3663:
10128:
9792:
9681:
9606:
9311:
9306:
8730:
8725:
8679:
8675:
8671:
8667:
8663:
8659:
8655:
8307:
7846:
7524:
4060:"Monoclonal Antibodies Key to Unlocking the Biosimilars Market"
3775:"Biotechnology Breakthrough In Breast Cancer Wins FDA Approval"
1997:(69 ed.). British Medical Association. 2015. p. 626.
1138:
983:
947:
872:
740:
488:
4095:"Brustkrebspräparat Herceptin im Fokus: Iraner kopieren Roche"
3638:
3367:
3141:
Ménard S, Pupa SM, Campiglio M, Tagliabue E (September 2003).
2095:"Trastuzumab-containing regimens for metastatic breast cancer"
1571:
1569:
1567:
1565:
1563:
950:, mediated by ERK1/2, and of the actin-depolymerizing protein
10160:
10156:
10152:
10148:
10144:
10140:
10136:
10132:
9847:
9746:
9421:
9361:
9175:
8898:
8894:
8890:
8886:
8377:
8241:
8160:
8156:
8055:
8051:
8047:
8043:
7952:
7948:
7799:
6049:
5775:
5609:
5558:
5038:
4852:. In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.).
4588:
3503:
2300:
2213:
1103:
89:
3957:"Emcure signs deal to manufacture Roche's anti-cancer drugs"
3715:
Drebin JA, Link VC, Weinberg RA, Greene MI (December 1986).
3140:
2510:"Development of Herceptin resistance in breast cancer cells"
2507:
9631:
8237:
8233:
8229:
8225:
8221:
8217:
8152:
8148:
8144:
8140:
8136:
8039:
8035:
8027:
8023:
8019:
8015:
8011:
8007:
8003:
7944:
7940:
7936:
7932:
7928:
7924:
7920:
7872:
7868:
7864:
7830:
7795:
7776:
6164:
5950:
5448:
5174:
5156:
5146:
5106:
4974:
4850:"Trastuzumab (Herceptin) Therapy and ERBB2 (HER2) Genotype"
3283:
2016:
2014:
1560:
1217:
Ogivri was approved for medical use in Canada in May 2019.
1092:
943:
919:
888:
884:
880:
468:
2917:
3324:
2303:"Trastuzumab containing regimens for early breast cancer"
2216:"Trastuzumab containing regimens for early breast cancer"
2064:
1683:
923:
868:
4804:
3714:
3416:
2011:
1014:(SISH/CISH/FISH). HER2 amplification can be detected by
4101:(in German). Archived from the original on 2 March 2016
3580:
3232:
2920:"Trastuzumab-induced cardiac dysfunction: A 'dual-hit'"
754:. As a result, regular cardiac screening with either a
670:
World Health Organization's List of Essential Medicines
661:
may harm the baby. Trastuzumab works by binding to the
10231:
Pituitary adenylate cyclase-activating peptide (PACAP)
3112:"HER2 Disease in the Metastatic and Adjuvant Settings"
2839:
2600:
1784:
1782:
1640:
1638:
1061:
The drug was first discovered by scientists including
938:(CDRs) leading to surface redistribution of ERBB2 and
10277:
7363:
3181:
2803:
2801:
1901:. The American Society of Health-System Pharmacists.
1418:
1416:
1385:
1383:
903:) to inside the cell, and turn genes on and off. The
6366:
4319:
1668:
1453:
1451:
1449:
1319:
1317:
1010:(IHC) and either silver, chromogenic or fluorescent
4366:"FDA approves Herzuma as a biosimilar to Herceptin"
2918:Zeglinski M, Ludke A, Jassal DS, Singal PK (2011).
2751:
1779:
1635:
1467:
1465:
10177:Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
9035:Glial cell line-derived neurotrophic factor (GDNF)
8688:Cleavage products/derivatives with unknown target:
4165:"FDA approves Ogivri as a biosimilar to Herceptin"
2798:
1646:"Trastuzumab Pregnancy and Breastfeeding Warnings"
1413:
1380:
1352:
1350:
1099:by the FDA and gained approval in September 1998.
1006:, the most commonly employed methods for this are
630:. It may be used by itself or together with other
4360:
4358:
4356:
3143:"Biologic and therapeutic role of HER2 in cancer"
2990:
1956:
1954:
1446:
1314:
10301:
10211:Macrophage-stimulating protein (MSP; HLP, HGFLP)
3532:. BioPortfolio.com. 14 June 2011. Archived from
3066:
1604:
1602:
1462:
1170:By 2014, around 20 companies, particularly from
400:
7852:Heparin-binding EGF-like growth factor (HB-EGF)
7535:Heparin-binding EGF-like growth factor (HB-EGF)
4506:"Summary Basis of Decision (SBD) for Trazimera"
3038:"Targeted Therapies for Breast Cancer Tutorial"
2209:
2207:
2205:
1502:
1500:
1498:
1347:
374:
4629:
4627:
4625:
4566:"Summary Basis of Decision (SBD) for Kanjinti"
4353:
4227:
4027:"Hospitals Furious at Cancer-Drug Price Hikes"
4024:
3498:
3496:
1951:
1817:
1815:
1705:"Herceptin (trastuzumab) powder for injection"
1237:Committee for Medicinal Products for Human Use
10340:World Health Organization essential medicines
10263:Additional growth factor receptor modulators:
7349:
6352:
4921:
4860:National Center for Biotechnology Information
4536:"Summary Basis of Decision (SBD) for Herzuma"
2461:
2261:
2259:
1599:
991:antibody-dependent cell-mediated cytotoxicity
626:. It is specifically used for cancer that is
8617:Insulin-like growth factor-2 (somatomedin A)
8499:Insulin-like growth factor-2 (somatomedin A)
8489:Insulin-like growth factor-1 (somatomedin C)
4476:"Summary Basis of Decision (SBD) for Ogivri"
2911:
2780:"12-month Herceptin treatment now available"
2550:
2294:
2202:
1697:
1495:
1183:Ministry of Health of the Russian Federation
863:gene) is amplified in 20–30% of early-stage
343:Unknown, possibly reticuloendothelial system
170:
4622:
3493:
2388:
2382:
2307:The Cochrane Database of Systematic Reviews
2220:The Cochrane Database of Systematic Reviews
2166:The Cochrane Database of Systematic Reviews
2102:The Cochrane Database of Systematic Reviews
1893:
1891:
1889:
1887:
1885:
1883:
1881:
1812:
7356:
7342:
6359:
6345:
4928:
4914:
2960:"Breast Cancer Care Trastuzumab factsheet"
2809:"Breast Cancer Care Trastuzumab factsheet"
2462:Le XF, Pruefer F, Bast RC (January 2005).
2457:
2455:
2453:
2256:
993:is another important mechanism of action.
518:
47:
4830:
4057:
4018:
3985:
3750:
3740:
3614:
3450:
3393:
3158:
3032:
3030:
2935:
2720:
2671:
2618:
2525:
2479:
2433:
2326:
2239:
2185:
2121:
2077:
1286:
1284:
837:Learn how and when to remove this message
780:Trastuzumab may harm a developing fetus.
456:
10221:Migration-stimulating factor (MSF; PRG4)
4763:(1st ed.). New York: Random House.
3361:
3286:New Trends in Cancer for the 21stCentury
3277:
2745:
2349:
2343:
1995:British national formulary : BNF 69
1878:
1259:Trastuzumab is also a component of some
725:
7550:Transforming growth factor alpha (TGFα)
4777:
4092:
3060:
2643:
2503:
2501:
2499:
2450:
2159:
2058:
1757:"Summary Basis of Decision - Ontruzant"
420:
14:
10302:
10124:Connective tissue growth factor (CTGF)
4758:
4672:from the original on 28 September 2019
4609:from the original on 21 September 2023
3849:from the original on 8 September 2017.
3836:
3803:
3134:
3069:Clinical Pharmacology and Therapeutics
3027:
2877:Clinical Pharmacology and Therapeutics
2594:
2415:
2409:
2160:Wilcken N (June 2014). Tovey D (ed.).
1581:Therapeutic Goods Administration (TGA)
1281:
1110:
996:
783:
509:
317:
10187:Hepatoma-derived growth factor (HDGF)
7337:
6340:
4909:
4792:from the original on 13 December 2019
4706:from the original on 20 December 2019
4380:from the original on 13 December 2019
4341:from the original on 18 December 2019
4066:. BioPharm International-04-01-2014.
3859:
3510:from the original on 27 November 2011
2984:
2265:
2072:. Geneva: World Health Organization.
1987:
1939:from the original on 15 December 2019
1905:from the original on 21 December 2016
1866:from the original on 26 November 2023
1254:
942:in CDRs and that the ERBB2-dependent
496:
302:
161:
143:
10315:Drugs developed by Hoffmann-La Roche
4874:from the original on 26 October 2020
4847:
4423:from the original on 31 October 2020
4307:from the original on 8 November 2020
4179:from the original on 3 December 2019
4039:from the original on 20 October 2015
4006:from the original on 4 February 2023
3937:from the original on 23 October 2013
2972:from the original on 23 October 2013
2924:Experimental and Clinical Cardiology
2821:from the original on 23 October 2013
2786:from the original on 20 January 2017
2496:
1935:(Press release). 10 September 2019.
1860:Union Register of medicinal products
1656:from the original on 3 December 2019
1518:from the original on 3 December 2023
1434:from the original on 7 December 2022
1368:from the original on 7 December 2022
1335:from the original on 5 December 2021
787:
391:
250:
4702:(Press release). 20 December 2019.
4376:(Press release). 18 December 2018.
4215:from the original on 29 August 2021
2709:The New England Journal of Medicine
2652:The New England Journal of Medicine
2607:The New England Journal of Medicine
2268:The New England Journal of Medicine
2141:from the original on 29 August 2021
1401:from the original on 13 August 2022
1091:developed trastuzumab jointly with
936:complementarity-determining regions
665:and slowing down cell replication.
476:
24:
10325:Drugs developed by Merck & Co.
4752:
4248:from the original on 4 August 2020
4025:Saporito, Bill (27 October 2014).
3562:from the original on 23 March 2012
3122:from the original on 10 April 2011
3048:from the original on 29 March 2011
2032:. 18 December 2015. Archived from
1836:from the original on 24 March 2020
1800:from the original on 4 August 2020
1767:from the original on 6 August 2022
1548:from the original on 10 March 2024
1027:copy number from microarray data.
734:
25:
10351:
4887:
4730:U.S. Food and Drug Administration
4666:U.S. Food and Drug Administration
4456:from the original on 28 July 2020
4074:from the original on 1 March 2016
3967:from the original on 2 April 2015
3818:from the original on 30 June 2016
3645:from the original on 11 June 2013
3109:
1975:from the original on 28 July 2020
1715:from the original on 8 March 2023
1623:from the original on 28 July 2020
1587:from the original on 30 July 2022
1302:from the original on 7 April 2017
1038:Fluorescent in situ hybridization
714:in combination with trastuzumab,
277:
193:
10330:Monoclonal antibodies for tumors
10287:
10206:Leukemia inhibitory factor (LIF)
4576:from the original on 30 May 2022
4546:from the original on 30 May 2022
4516:from the original on 31 May 2022
4486:from the original on 31 May 2022
4390:
4327:"Drug Approval Package: Herzuma"
4274:from the original on 4 June 2018
4189:
3986:Rajagopla D (26 November 2015).
3785:from the original on 1 July 2016
3481:from the original on 23 May 2009
2582:
2368:10.1053/j.seminoncol.2003.08.008
2046:
1483:from the original on 16 May 2021
1124:for a full course of treatment.
814:Capitalization, syntax and tone.
792:
549:
543:
9374:Negative allosteric modulators:
4736:from the original on 4 May 2022
4718:
4684:
4654:
4599:"Herwenda: Pending EC decision"
4558:
4528:
4498:
4468:
4435:
4402:
4286:
4260:
4201:
4157:
4127:
4086:
4051:
3979:
3949:
3922:
3896:
3853:
3830:
3797:
3767:
3708:
3657:
3631:
3574:
3548:
3522:
3506:. ventanamed.com. 25 May 2012.
3467:
3410:
3318:
3226:
3175:
3103:
2952:
2868:
2833:
2772:
2754:The New Zealand Medical Journal
2696:
2572:from the original on 5 May 2021
2416:Yu D, Hung MC (December 2000).
2153:
2086:
1917:
1848:
1749:
1727:
879:pathway includes the receptors
675:
119:Herceptin, Herceptin SC, others
9692:Gossypetin (3,5,7,8,3',4'-HHF)
8883:Platelet-derived growth factor
4780:"The selling of a wonder drug"
4093:Feldges D (18 February 2016).
2319:10.1002/14651858.CD006243.pub2
2232:10.1002/14651858.CD006243.pub2
2114:10.1002/14651858.CD006242.pub2
1856:"Herwenda Product information"
1741:. 7 April 2022. Archived from
1530:
1159:
1148:1,200) in the Indian market.
1132:Pharmaceutical Benefits Scheme
710:In May 2021, the FDA approved
561:
555:
537:
290:
57:(cyan) binding HER2/neu (gold)
13:
1:
9898:Placental growth factor (PGF)
4141:. 3 June 2016. Archived from
3904:"Listing of Herceptin on PBS"
1577:"Trastucip and Tuzucip APMDS"
1274:
1047:
640:injection just under the skin
10310:Drugs developed by Genentech
10182:Glia maturation factor (GMF)
8691:Glypromate (GPE, (1-3)IGF-1)
4698:Food and Drug Administration
4372:Food and Drug Administration
4333:Food and Drug Administration
4171:Food and Drug Administration
4058:Challener C (1 April 2014).
3294:10.1007/978-1-4615-0081-0_21
2842:Journal of Clinical Oncology
2564:Food and Drug Administration
2028:Food and Drug Administration
1931:Food and Drug Administration
1115:
610:, sold under the brand name
7:
4870:. Bookshelf ID: NBK310376.
4778:Boseley S (29 March 2006).
1102:Biocon Ltd and its partner
812:. The specific problem is:
10:
10356:
10114:Colony-stimulating factors
10106:Additional growth factors:
5431:Tyrosine kinase inhibitors
4855:Medical Genetics Summaries
3862:The Hastings Center Report
2782:. New Zealand Government.
2082:. WHO/MHP/HPS/EML/2023.02.
1739:Roche Products Pty Limited
1709:Roche Products Pty Limited
1163:
1087:, that premiered in 2008.
1056:
765:Trastuzumab downregulates
636:slow injection into a vein
634:. Trastuzumab is given by
527:Chemical and physical data
29:
10098:
9885:
9780:
9549:
9462:SNA-120 (pegylated K252a)
9289:
9280:
9260:
9174:
9151:
9120:
9089:
9058:
9022:
9013:
8865:
8708:
8641:
8634:(against IGF-1 and IGF-2)
8603:
8596:(against IGF-1 and IGF-2)
8470:
8461:
8279:
8256:
8196:
8115:
7982:
7899:
7890:
7829:
7775:
7688:
7492:
7483:
7452:
7374:
7294:
7264:
7241:
6904:
6876:Mirvetuximab soravtansine
6791:
6645:
6384:
6375:
6021:
5798:
5439:
5429:
5297:Mirvetuximab soravtansine
5189:
5070:
5030:
4965:
4952:
4899:National Cancer Institute
4639:European Medicines Agency
4603:European Medicines Agency
4448:European Medicines Agency
4415:European Medicines Agency
4299:European Medicines Agency
4240:European Medicines Agency
4119:: CS1 maint: unfit URL (
3837:Palmer E (3 March 2017).
3042:National Cancer Institute
2178:10.1002/14651858.ED000083
2066:World Health Organization
1967:European Medicines Agency
1828:European Medicines Agency
1615:European Medicines Agency
1512:European Medicines Agency
1292:"Trastuzumab - Drugs.com"
1241:European Medicines Agency
587:
570:
531:
526:
507:
487:
467:
447:
431:
411:
385:
365:
360:
347:
337:
329:
267:
262:
237:
225:
207:
181:
151:
133:
123:
113:
108:
96:
79:
69:
62:
46:
8298:Hepatocyte growth factor
7857:Neuregulins (heregulins)
7788:Neuregulins (heregulins)
7732:Trastuzumab duocarmazine
7445:(against angiopoietin 2)
7439:(against angiopoietin 3)
5441:Receptor tyrosine kinase
4967:Receptor tyrosine kinase
3804:Altman L (18 May 1998).
3558:. ASCO. 6 October 2009.
2391:Clinical Cancer Research
1261:antibody-drug conjugates
1120:Trastuzumab costs about
752:congestive heart failure
30:Not to be confused with
7645:Depatuxizumab mafodotin
7272:Depatuxizumab mafodotin
7213:Tucotuzumab celmoleukin
7164:Rovalpituzumab tesirine
7079:Lorvotuzumab mertansine
6969:Clivatuzumab tetraxetan
5031:Others for solid tumors
4937:Targeted cancer therapy
3742:10.1073/pnas.83.23.9129
3081:10.1038/sj.clpt.6100160
1235:In September 2023, the
1042:Ventana Medical Systems
632:chemotherapy medication
298: / Schedule D
10268:(neurotrophin mixture)
10256:Wnt signaling proteins
9937:Allosteric modulators:
9657:Norwogonin (5,7,8-THF)
7877:5 (tomoregulin, TMEFF)
7727:Trastuzumab deruxtecan
7365:Growth factor receptor
7233:Vorsetuzumab mafodotin
7189:Tacatuzumab tetraxetan
6994:Denintuzumab mafodotin
6939:Bivatuzumab mertansine
6866:Loncastuximab tesirine
6856:Indatuximab ravtansine
6733:Naptumomab estafenatox
5292:Loncastuximab tesirine
5021:Trastuzumab deruxtecan
4064:BioPharm International
3160:10.1038/sj.onc.1206779
2814:. Breast Cancer Care.
2435:10.1038/sj.onc.1203972
1269:trastuzumab deruxtecan
1137:Roche has agreed with
628:HER2 receptor positive
10196:T-cell growth factors
8453:Telisotuzumab vedotin
7737:Trastuzumab emtansine
7218:Vandortuzumab vedotin
7169:Sacituzumab govitecan
7059:Inotuzumab ozogamicin
7044:Gemtuzumab ozogamicin
6974:Cofetuzumab pelidotin
6954:Cantuzumab ravtansine
6949:Cantuzumab mertansine
6768:Nofetumomab merpentan
6728:Moxetumomab pasudotox
6482:Glembatumumab vedotin
6368:Monoclonal antibodies
5367:Sacituzumab govitecan
5307:Moxetumomab pasudotox
5277:Inotuzumab ozogamicin
5180:Gemtuzumab ozogamicin
5016:Trastuzumab emtansine
4957:monoclonal antibodies
4941:antineoplastic agents
4605:. 15 September 2023.
4452:. 17 September 2018.
4419:. 17 September 2018.
4303:. 17 September 2018.
4244:. 17 September 2018.
3874:10.1353/hcr.2006.0040
3781:. 25 September 1998.
2854:10.1200/JCO.20.5.1215
2362:(5 Suppl 16): 54–64.
1971:. 17 September 2018.
1832:. 17 September 2018.
1796:. 30 September 2019.
1265:trastuzumab emtansine
1012:in situ hybridisation
961:Normal cell division—
726:Duration of treatment
32:Trastuzumab emtansine
8781:EVT-901 (SAR-127963)
8514:Mecasermin rinfabate
7265:Chimeric + humanized
7069:Lifastuzumab vedotin
6929:Belantamab mafodotin
6698:Ibritumomab tiuxetan
6663:Anatumomab mafenatox
5222:Belantamab mafodotin
4823:10.3747/co.v16i4.469
4099:Neue Zürcher Zeitung
3910:on 12 September 2009
2889:10.1038/clpt.2011.74
2722:10.1056/NEJMoa053028
2664:10.1056/NEJMoa052306
2620:10.1056/NEJMoa052122
2527:10.1002/cyto.a.10095
2356:Seminars in Oncology
2280:10.1056/NEJMra043186
1862:. 16 November 2023.
1514:. 15 November 2023.
1430:. 14 February 2022.
1008:immunohistochemistry
855:gene (also known as
819:improve this section
808:to meet Knowledge's
232:Antineoplastic agent
7184:Sofituzumab vedotin
7154:Polatuzumab vedotin
7149:Pinatuzumab vedotin
7134:Oportuzumab monatox
6964:Citatuzumab bogatox
6826:Derlotuximab biotin
6811:Brentuximab vedotin
6763:Taplitumomab paptox
6753:Satumomab pendetide
6723:Nacolomab tafenatox
6658:Altumomab pentetate
6075:Denileukin diftitox
5737:(ALK, ROS1, NTRK),
5342:Polatuzumab vedotin
5332:Oportuzumab monatox
4572:. 23 October 2014.
4542:. 23 October 2014.
4512:. 23 October 2014.
4482:. 23 October 2014.
4337:. 7 February 2019.
4175:. 1 December 2017.
3733:1986PNAS...83.9129D
3678:1984Natur.312..513S
3641:. cancer.ucla.edu.
3599:2014NatSR...4E4483A
3443:10.1038/nature10983
3435:2012Natur.486..346.
3386:10.1136/mp.50.5.254
3374:Molecular Pathology
3247:1984Natur.312..545D
3204:10.1038/nature01392
3196:2003Natur.421..756C
2481:10.4161/cc.4.1.1360
1763:. 23 October 2014.
1479:. 6 February 2023.
1397:. 31 January 2023.
1364:. 8 February 2021.
1331:. 13 October 2022.
1251:medicinal product.
1111:Society and culture
1016:virtual karyotyping
1004:clinical laboratory
997:Predicting response
784:Mechanism of action
720:platinum-containing
616:monoclonal antibody
614:among others, is a
286:(Prescription only)
64:Monoclonal antibody
43:
9947:Kinase inhibitors:
9810:Kinase inhibitors:
9709:Kinase inhibitors:
9384:Kinase inhibitors:
9199:Kinase inhibitors:
9159:Kinase inhibitors:
9140:Kinase inhibitors:
9109:Kinase inhibitors:
9078:Kinase inhibitors:
9047:Kinase inhibitors:
8907:Kinase inhibitors:
8521:Kinase inhibitors:
8315:Kinase inhibitors:
8104:Kinase inhibitors:
8097:Aprutumab ixadotin
7744:Kinase inhibitors:
7557:Kinase inhibitors:
7414:Kinase inhibitors:
7321:Never to phase III
6683:Capromab pendetide
6457:Enfortumab vedotin
5761:(ROS1, TRK, ALK),
5267:Enfortumab vedotin
3992:The Economic Times
3961:The Times Of India
3811:The New York Times
3587:Scientific Reports
3116:Medscape Education
2036:on 28 January 2017
1745:on 8 January 2023.
1255:Related conjugates
1174:, were developing
1067:H. Michael Shepard
651:allergic reactions
39:
10275:
10274:
9881:
9880:
9642:N-Acetylserotonin
9541:ReN-1820 (TrkAd5)
9170:
9169:
8704:
8703:
8649:Binding proteins:
8308:Dihexa (PNB-0408)
8275:
8274:
7886:
7885:
7800:6 (neuroglycan C)
7520:EGF (urogastrone)
7498:
7331:
7330:
7290:
7289:
6612:Tisotumab vedotin
6334:
6333:
6017:
6016:
5425:
5424:
5407:Tisotumab vedotin
4901:. 5 October 2006.
4759:Bazell R (1998).
3727:(23): 9129–9133.
3672:(5994): 513–516.
3639:"cancer.ucla.edu"
3607:10.1038/srep04483
3429:(7403): 346–352.
3303:978-0-306-47762-1
3241:(5994): 545–548.
3190:(6924): 756–760.
3153:(42): 6570–6578.
2658:(16): 1659–1672.
2613:(16): 1673–1684.
2514:Cytometry. Part A
2428:(53): 6115–6121.
2397:(14): 5078–5084.
2004:978-0-85711-156-2
847:
846:
839:
810:quality standards
801:This section may
605:
604:
321:
306:
293:
281:
197:
164:
16:(Redirected from
10347:
10292:
10291:
10290:
10283:
10087:Decoy receptors:
10060:Alacizumab pegol
9538:Decoy receptors:
9287:
9286:
9192:Stem cell factor
9133:Persephin (PSPN)
9071:Neurturin (NRTN)
9020:
9019:
8857:LEVI-04 (p75-Fc)
8854:Decoy receptors:
8468:
8467:
7897:
7896:
7496:
7490:
7489:
7358:
7351:
7344:
7335:
7334:
7243:Rat/mouse hybrid
6382:
6381:
6361:
6354:
6347:
6338:
6337:
6048:peptide against
5621:(AXL, ALK, LTK))
5437:
5436:
5247:Dinutuximab beta
4963:
4962:
4930:
4923:
4916:
4907:
4906:
4902:
4883:
4881:
4879:
4844:
4834:
4811:Current Oncology
4801:
4799:
4797:
4774:
4746:
4745:
4743:
4741:
4722:
4716:
4715:
4713:
4711:
4688:
4682:
4681:
4679:
4677:
4658:
4652:
4650:
4648:
4646:
4631:
4620:
4618:
4616:
4614:
4595:
4586:
4585:
4583:
4581:
4562:
4556:
4555:
4553:
4551:
4532:
4526:
4525:
4523:
4521:
4502:
4496:
4495:
4493:
4491:
4472:
4466:
4465:
4463:
4461:
4443:"Trazimera EPAR"
4439:
4433:
4432:
4430:
4428:
4406:
4400:
4394:
4393:
4389:
4387:
4385:
4362:
4351:
4350:
4348:
4346:
4323:
4317:
4316:
4314:
4312:
4290:
4284:
4283:
4281:
4279:
4264:
4258:
4257:
4255:
4253:
4235:"Ontruzant EPAR"
4231:
4225:
4224:
4222:
4220:
4205:
4199:
4193:
4192:
4188:
4186:
4184:
4161:
4155:
4154:
4152:
4150:
4131:
4125:
4124:
4118:
4110:
4108:
4106:
4090:
4084:
4083:
4081:
4079:
4055:
4049:
4048:
4046:
4044:
4022:
4016:
4015:
4013:
4011:
3983:
3977:
3976:
3974:
3972:
3963:. 2 March 2012.
3953:
3947:
3946:
3944:
3942:
3926:
3920:
3919:
3917:
3915:
3900:
3894:
3893:
3857:
3851:
3850:
3834:
3828:
3827:
3825:
3823:
3801:
3795:
3794:
3792:
3790:
3771:
3765:
3764:
3754:
3744:
3712:
3706:
3705:
3686:10.1038/312513a0
3661:
3655:
3654:
3652:
3650:
3635:
3629:
3628:
3618:
3578:
3572:
3571:
3569:
3567:
3552:
3546:
3545:
3543:
3541:
3536:on 25 March 2012
3526:
3520:
3519:
3517:
3515:
3504:"ventanamed.com"
3500:
3491:
3490:
3488:
3486:
3475:"Product groups"
3471:
3465:
3464:
3454:
3414:
3408:
3407:
3397:
3365:
3359:
3358:
3322:
3316:
3315:
3281:
3275:
3274:
3255:10.1038/312545a0
3230:
3224:
3223:
3179:
3173:
3172:
3162:
3138:
3132:
3131:
3129:
3127:
3107:
3101:
3100:
3064:
3058:
3057:
3055:
3053:
3034:
3025:
3024:
2988:
2982:
2981:
2979:
2977:
2971:
2964:
2956:
2950:
2949:
2939:
2915:
2909:
2908:
2872:
2866:
2865:
2848:(5): 1215–1221.
2837:
2831:
2830:
2828:
2826:
2820:
2813:
2805:
2796:
2795:
2793:
2791:
2776:
2770:
2769:
2749:
2743:
2742:
2724:
2700:
2694:
2693:
2675:
2647:
2641:
2640:
2622:
2598:
2592:
2586:
2585:
2581:
2579:
2577:
2554:
2548:
2547:
2529:
2505:
2494:
2493:
2483:
2459:
2448:
2447:
2437:
2413:
2407:
2406:
2386:
2380:
2379:
2347:
2341:
2340:
2330:
2298:
2292:
2291:
2263:
2254:
2253:
2243:
2211:
2200:
2199:
2189:
2157:
2151:
2150:
2148:
2146:
2140:
2125:
2099:
2090:
2084:
2083:
2081:
2062:
2056:
2050:
2049:
2045:
2043:
2041:
2018:
2009:
2008:
1991:
1985:
1984:
1982:
1980:
1962:"Herceptin EPAR"
1958:
1949:
1948:
1946:
1944:
1921:
1915:
1914:
1912:
1910:
1895:
1876:
1875:
1873:
1871:
1852:
1846:
1845:
1843:
1841:
1819:
1810:
1809:
1807:
1805:
1786:
1777:
1776:
1774:
1772:
1753:
1747:
1746:
1731:
1725:
1724:
1722:
1720:
1701:
1695:
1694:
1692:
1690:
1680:nctr-crs.fda.gov
1672:
1666:
1665:
1663:
1661:
1642:
1633:
1632:
1630:
1628:
1606:
1597:
1596:
1594:
1592:
1583:. 29 July 2022.
1573:
1558:
1557:
1555:
1553:
1544:. 28 July 2023.
1534:
1528:
1527:
1525:
1523:
1504:
1493:
1492:
1490:
1488:
1469:
1460:
1455:
1444:
1443:
1441:
1439:
1420:
1411:
1410:
1408:
1406:
1387:
1378:
1377:
1375:
1373:
1354:
1345:
1344:
1342:
1340:
1321:
1312:
1311:
1309:
1307:
1288:
1172:emerging markets
1147:
1123:
926:pathway and the
842:
835:
831:
828:
822:
796:
795:
788:
775:PI3K/AKT pathway
760:echocardiography
716:fluoropyrimidine
601:
600:
593:
582:
580:
563:
557:
551:
545:
539:
522:
511:
500:
480:
460:
424:
404:
394:
393:
378:
352:
319:
316:
311:
304:
301:
292:
289:
279:
276:
254:
195:
192:
174:
163:
160:
147:
51:
44:
42:
38:
21:
10355:
10354:
10350:
10349:
10348:
10346:
10345:
10344:
10335:Specialty drugs
10300:
10299:
10298:
10288:
10286:
10278:
10276:
10271:
10216:Midkine (NEGF2)
10094:
9877:
9776:
9545:
9483:ABT-110 (PG110)
9276:
9256:
9166:
9147:
9116:
9085:
9054:
9009:
8861:
8799:ABT-110 (PG110)
8700:
8637:
8599:
8457:
8271:
8252:
8192:
8189:(against FGF23)
8111:
7978:
7882:
7825:
7771:
7684:
7495:
7479:
7448:
7370:
7362:
7332:
7327:
7326:
7311:Clinical trials
7286:
7260:
7237:
6900:
6787:
6641:
6371:
6365:
6335:
6330:
6184:Pi3K inhibitors
6082:mTOR inhibitors
6013:
5794:
5765:(VEGFR, FGFR),
5421:
5185:
5066:
5026:
4948:
4934:
4893:
4890:
4877:
4875:
4848:Dean L (2015).
4795:
4793:
4771:
4755:
4753:Further reading
4750:
4749:
4739:
4737:
4724:
4723:
4719:
4709:
4707:
4690:
4689:
4685:
4675:
4673:
4660:
4659:
4655:
4644:
4642:
4633:
4632:
4623:
4612:
4610:
4597:
4596:
4589:
4579:
4577:
4564:
4563:
4559:
4549:
4547:
4534:
4533:
4529:
4519:
4517:
4504:
4503:
4499:
4489:
4487:
4474:
4473:
4469:
4459:
4457:
4441:
4440:
4436:
4426:
4424:
4410:"Kanjinti EPAR"
4408:
4407:
4403:
4391:
4383:
4381:
4364:
4363:
4354:
4344:
4342:
4325:
4324:
4320:
4310:
4308:
4292:
4291:
4287:
4277:
4275:
4266:
4265:
4261:
4251:
4249:
4233:
4232:
4228:
4218:
4216:
4207:
4206:
4202:
4190:
4182:
4180:
4163:
4162:
4158:
4148:
4146:
4145:on 11 June 2016
4133:
4132:
4128:
4112:
4111:
4104:
4102:
4091:
4087:
4077:
4075:
4056:
4052:
4042:
4040:
4023:
4019:
4009:
4007:
3984:
3980:
3970:
3968:
3955:
3954:
3950:
3940:
3938:
3929:
3927:
3923:
3913:
3911:
3902:
3901:
3897:
3858:
3854:
3835:
3831:
3821:
3819:
3802:
3798:
3788:
3786:
3773:
3772:
3768:
3713:
3709:
3662:
3658:
3648:
3646:
3637:
3636:
3632:
3579:
3575:
3565:
3563:
3554:
3553:
3549:
3539:
3537:
3528:
3527:
3523:
3513:
3511:
3502:
3501:
3494:
3484:
3482:
3473:
3472:
3468:
3415:
3411:
3366:
3362:
3327:Nature Medicine
3323:
3319:
3304:
3282:
3278:
3231:
3227:
3180:
3176:
3139:
3135:
3125:
3123:
3108:
3104:
3065:
3061:
3051:
3049:
3036:
3035:
3028:
2993:Nature Medicine
2989:
2985:
2975:
2973:
2969:
2962:
2958:
2957:
2953:
2916:
2912:
2873:
2869:
2838:
2834:
2824:
2822:
2818:
2811:
2807:
2806:
2799:
2789:
2787:
2778:
2777:
2773:
2760:(1256): U2593.
2750:
2746:
2701:
2697:
2648:
2644:
2599:
2595:
2583:
2575:
2573:
2556:
2555:
2551:
2506:
2497:
2460:
2451:
2414:
2410:
2387:
2383:
2348:
2344:
2313:(4): CD006243.
2299:
2295:
2264:
2257:
2226:(4): CD006243.
2212:
2203:
2172:(6): ED000083.
2158:
2154:
2144:
2142:
2138:
2108:(6): CD006242.
2097:
2091:
2087:
2063:
2059:
2047:
2039:
2037:
2020:
2019:
2012:
2005:
1993:
1992:
1988:
1978:
1976:
1960:
1959:
1952:
1942:
1940:
1923:
1922:
1918:
1908:
1906:
1897:
1896:
1879:
1869:
1867:
1854:
1853:
1849:
1839:
1837:
1821:
1820:
1813:
1803:
1801:
1788:
1787:
1780:
1770:
1768:
1755:
1754:
1750:
1733:
1732:
1728:
1718:
1716:
1703:
1702:
1698:
1688:
1686:
1674:
1673:
1669:
1659:
1657:
1644:
1643:
1636:
1626:
1624:
1619:. 26 May 2020.
1610:"Zercepac EPAR"
1608:
1607:
1600:
1590:
1588:
1575:
1574:
1561:
1551:
1549:
1536:
1535:
1531:
1521:
1519:
1508:"Herwenda EPAR"
1506:
1505:
1496:
1486:
1484:
1471:
1470:
1463:
1456:
1447:
1437:
1435:
1422:
1421:
1414:
1404:
1402:
1389:
1388:
1381:
1371:
1369:
1356:
1355:
1348:
1338:
1336:
1323:
1322:
1315:
1305:
1303:
1290:
1289:
1282:
1277:
1257:
1202:Samsung Bioepis
1191:trade sanctions
1168:
1162:
1153:specialty drugs
1145:
1121:
1118:
1113:
1075:Robert Weinberg
1059:
1050:
999:
843:
832:
826:
823:
816:
797:
793:
786:
737:
735:Adverse effects
728:
678:
596:
594:
591:(what is this?)
588:
578:
576:
566:
560:
554:
548:
542:
503:
483:
463:
443:
427:
407:
390:
381:
350:
331:Pharmacokinetic
325:
309:
258:
210:
203:
184:
177:
58:
35:
28:
23:
22:
15:
12:
11:
5:
10353:
10343:
10342:
10337:
10332:
10327:
10322:
10317:
10312:
10297:
10296:
10273:
10272:
10270:
10269:
10259:
10258:
10253:
10246:Thrombopoietin
10243:
10238:
10233:
10228:
10223:
10218:
10213:
10208:
10203:
10189:
10184:
10179:
10174:
10167:Erythropoietin
10164:
10126:
10121:
10111:
10109:Adrenomedullin
10102:
10100:
10096:
10095:
10093:
10092:
10083:
10082:
10077:
10072:
10067:
10062:
10053:
10052:
10047:
10042:
10037:
10032:
10027:
10022:
10017:
10012:
10007:
10002:
9997:
9992:
9987:
9982:
9977:
9972:
9967:
9962:
9957:
9952:
9943:
9942:
9933:
9932:
9910:
9905:
9900:
9891:
9889:
9883:
9882:
9879:
9878:
9876:
9875:
9870:
9865:
9860:
9855:
9850:
9845:
9840:
9835:
9830:
9825:
9820:
9815:
9806:
9805:
9800:
9795:
9786:
9784:
9778:
9777:
9775:
9774:
9769:
9764:
9759:
9754:
9749:
9744:
9739:
9734:
9729:
9724:
9719:
9714:
9705:
9704:
9695:
9694:
9689:
9684:
9675:
9674:
9669:
9664:
9659:
9654:
9649:
9644:
9639:
9634:
9629:
9624:
9619:
9614:
9609:
9604:
9599:
9594:
9589:
9584:
9579:
9574:
9572:4'-DMA-7,8-DHF
9569:
9564:
9555:
9553:
9547:
9546:
9544:
9543:
9534:
9533:
9521:
9520:
9515:
9510:
9505:
9500:
9495:
9490:
9485:
9466:
9465:
9459:
9454:
9449:
9444:
9439:
9434:
9429:
9424:
9419:
9414:
9409:
9404:
9399:
9394:
9389:
9380:
9379:
9370:
9369:
9364:
9359:
9354:
9345:
9344:
9339:
9334:
9332:Gambogic amide
9329:
9324:
9319:
9314:
9309:
9304:
9295:
9293:
9284:
9278:
9277:
9275:
9274:
9266:
9264:
9258:
9257:
9255:
9254:
9249:
9244:
9239:
9234:
9229:
9224:
9219:
9214:
9209:
9204:
9195:
9194:
9189:
9180:
9178:
9172:
9171:
9168:
9167:
9165:
9164:
9155:
9153:
9149:
9148:
9146:
9145:
9136:
9135:
9126:
9124:
9118:
9117:
9115:
9114:
9105:
9104:
9102:Artemin (ARTN)
9095:
9093:
9087:
9086:
9084:
9083:
9074:
9073:
9064:
9062:
9056:
9055:
9053:
9052:
9043:
9042:
9037:
9028:
9026:
9017:
9011:
9010:
9008:
9007:
9002:
8997:
8988:
8987:
8982:
8977:
8972:
8967:
8962:
8957:
8952:
8947:
8942:
8937:
8932:
8927:
8922:
8917:
8912:
8903:
8902:
8880:
8871:
8869:
8863:
8862:
8860:
8859:
8850:
8849:
8837:
8836:
8831:
8826:
8821:
8816:
8811:
8806:
8801:
8789:
8788:
8783:
8778:
8773:
8764:
8763:
8758:
8753:
8748:
8743:
8738:
8733:
8728:
8723:
8714:
8712:
8706:
8705:
8702:
8701:
8699:
8698:
8693:
8684:
8683:
8645:
8643:
8639:
8638:
8636:
8635:
8629:
8620:
8619:
8609:
8607:
8601:
8600:
8598:
8597:
8591:
8586:
8581:
8576:
8571:
8566:
8561:
8556:
8547:
8546:
8541:
8536:
8531:
8526:
8517:
8516:
8511:
8506:
8501:
8496:
8491:
8486:
8476:
8474:
8465:
8459:
8458:
8456:
8455:
8450:
8445:
8440:
8435:
8430:
8425:
8416:
8415:
8410:
8405:
8400:
8395:
8390:
8385:
8380:
8375:
8370:
8365:
8360:
8355:
8350:
8345:
8340:
8335:
8330:
8325:
8320:
8311:
8310:
8301:
8300:
8295:
8285:
8283:
8277:
8276:
8273:
8272:
8270:
8269:
8260:
8258:
8254:
8253:
8251:
8250:
8245:
8211:
8202:
8200:
8194:
8193:
8191:
8190:
8180:
8179:
8174:
8169:
8164:
8130:
8121:
8119:
8113:
8112:
8110:
8109:
8100:
8099:
8094:
8085:
8084:
8079:
8074:
8069:
8064:
8059:
7997:
7988:
7986:
7980:
7979:
7977:
7976:
7971:
7966:
7961:
7956:
7914:
7905:
7903:
7894:
7888:
7887:
7884:
7883:
7881:
7880:
7854:
7849:
7844:
7835:
7833:
7827:
7826:
7824:
7823:
7818:
7813:
7804:
7803:
7781:
7779:
7773:
7772:
7770:
7769:
7764:
7759:
7754:
7749:
7740:
7739:
7734:
7729:
7724:
7719:
7714:
7705:
7704:
7694:
7692:
7686:
7685:
7683:
7682:
7677:
7672:
7667:
7662:
7657:
7652:
7647:
7642:
7637:
7628:
7627:
7622:
7617:
7612:
7607:
7602:
7597:
7592:
7587:
7582:
7577:
7572:
7567:
7562:
7553:
7552:
7547:
7542:
7537:
7532:
7527:
7522:
7517:
7512:
7502:
7500:
7487:
7481:
7480:
7478:
7477:
7472:
7467:
7458:
7456:
7450:
7449:
7447:
7446:
7440:
7430:
7429:
7424:
7419:
7410:
7409:
7407:Angiopoietin 3
7404:
7402:Angiopoietin 2
7395:
7394:
7392:Angiopoietin 4
7389:
7387:Angiopoietin 1
7380:
7378:
7372:
7371:
7361:
7360:
7353:
7346:
7338:
7329:
7328:
7325:
7324:
7323:
7322:
7319:
7308:
7302:
7296:
7295:
7292:
7291:
7288:
7287:
7285:
7284:
7279:
7277:Duvortuxizumab
7274:
7268:
7266:
7262:
7261:
7259:
7258:
7253:
7247:
7245:
7239:
7238:
7236:
7235:
7230:
7225:
7220:
7215:
7210:
7196:
7191:
7186:
7181:
7176:
7171:
7166:
7161:
7156:
7151:
7146:
7141:
7136:
7131:
7126:
7121:
7116:
7111:
7106:
7101:
7096:
7091:
7086:
7081:
7076:
7071:
7066:
7061:
7056:
7051:
7046:
7041:
7036:
7031:
7026:
7021:
7016:
7011:
7006:
7001:
6996:
6991:
6986:
6981:
6976:
6971:
6966:
6961:
6956:
6951:
6946:
6944:Brontictuzumab
6941:
6936:
6931:
6926:
6921:
6916:
6910:
6908:
6902:
6901:
6899:
6898:
6893:
6888:
6883:
6878:
6873:
6868:
6863:
6858:
6853:
6848:
6843:
6838:
6833:
6828:
6823:
6818:
6813:
6808:
6803:
6797:
6795:
6789:
6788:
6786:
6785:
6780:
6775:
6770:
6765:
6760:
6755:
6750:
6745:
6740:
6735:
6730:
6725:
6720:
6715:
6710:
6705:
6700:
6695:
6690:
6685:
6680:
6675:
6670:
6665:
6660:
6655:
6649:
6647:
6643:
6642:
6640:
6639:
6634:
6629:
6624:
6619:
6614:
6609:
6604:
6599:
6594:
6589:
6584:
6579:
6574:
6569:
6564:
6559:
6554:
6549:
6544:
6539:
6534:
6529:
6524:
6519:
6514:
6509:
6504:
6499:
6494:
6489:
6484:
6479:
6474:
6469:
6464:
6459:
6454:
6449:
6444:
6439:
6434:
6429:
6424:
6419:
6414:
6411:+hyaluronidase
6404:
6399:
6394:
6388:
6386:
6379:
6373:
6372:
6364:
6363:
6356:
6349:
6341:
6332:
6331:
6329:
6328:
6323:
6318:
6313:
6308:
6303:
6298:
6293:
6288:
6283:
6278:
6273:
6268:
6263:
6258:
6253:
6248:
6243:
6238:
6233:
6228:
6223:
6218:
6213:
6212:
6211:
6206:
6201:
6196:
6191:
6181:
6180:
6179:
6174:
6161:
6160:
6159:
6154:
6149:
6144:
6139:
6131:CDK inhibitors
6127:
6126:
6125:
6120:
6115:
6102:
6101:
6100:
6095:
6090:
6078:
6062:
6042:
6030:fusion protein
6025:
6023:
6019:
6018:
6015:
6014:
6012:
6011:
6010:
6009:
6004:
5999:
5994:
5989:
5976:
5975:
5974:
5973:
5968:
5963:
5946:
5945:
5944:
5943:
5938:
5933:
5928:
5915:
5914:
5913:
5912:
5907:
5902:
5897:
5892:
5887:
5882:
5869:
5868:
5862:
5850:
5849:
5848:
5847:
5842:
5837:
5832:
5827:
5822:
5817:
5804:
5802:
5796:
5795:
5793:
5792:
5771:
5770:
5769:(VEGFR, EGFR).
5725:
5724:
5723:
5722:
5717:
5712:
5699:
5698:
5697:
5696:
5691:
5686:
5681:
5676:
5671:
5666:
5661:
5656:
5651:
5646:
5641:
5636:
5623:
5622:
5606:
5600:
5595:
5590:
5585:
5580:
5575:
5570:
5550:
5549:
5548:
5547:
5542:
5537:
5527:HER1/EGFR and
5523:
5522:
5516:
5511:
5506:
5501:
5496:
5491:
5486:
5481:
5476:
5471:
5466:
5461:
5445:
5443:
5434:
5427:
5426:
5423:
5422:
5420:
5419:
5414:
5409:
5404:
5399:
5394:
5389:
5384:
5379:
5374:
5369:
5364:
5359:
5354:
5349:
5344:
5339:
5334:
5329:
5324:
5319:
5314:
5309:
5304:
5299:
5294:
5289:
5284:
5279:
5274:
5269:
5264:
5259:
5254:
5249:
5244:
5239:
5234:
5229:
5224:
5219:
5214:
5209:
5206:+hyaluronidase
5199:
5193:
5191:
5187:
5186:
5184:
5183:
5166:
5165:
5139:
5134:
5129:
5124:
5119:
5114:
5080:
5078:
5068:
5067:
5065:
5064:
5052:
5046:
5034:
5032:
5028:
5027:
5025:
5024:
5018:
5013:
5010:+hyaluronidase
4993:
4987:
4971:
4969:
4960:
4950:
4949:
4933:
4932:
4925:
4918:
4910:
4904:
4903:
4889:
4888:External links
4886:
4885:
4884:
4845:
4802:
4775:
4769:
4754:
4751:
4748:
4747:
4732:. 4 May 2022.
4717:
4683:
4668:. 3 May 2019.
4653:
4641:. 26 July 2024
4621:
4587:
4557:
4527:
4497:
4467:
4434:
4401:
4352:
4318:
4294:"Herzuma EPAR"
4285:
4259:
4226:
4200:
4156:
4139:Cancer Network
4126:
4085:
4050:
4017:
3978:
3948:
3921:
3895:
3852:
3829:
3796:
3766:
3707:
3656:
3630:
3573:
3547:
3521:
3492:
3466:
3409:
3380:(5): 254–256.
3360:
3333:(4): 443–446.
3317:
3302:
3276:
3225:
3174:
3133:
3102:
3075:(6): 887–892.
3059:
3026:
2999:(5): 548–552.
2983:
2951:
2910:
2883:(1): 126–132.
2867:
2832:
2797:
2771:
2744:
2715:(8): 809–820.
2695:
2642:
2593:
2568:. 5 May 2021.
2549:
2495:
2449:
2408:
2381:
2342:
2293:
2255:
2201:
2152:
2085:
2057:
2010:
2003:
1986:
1950:
1916:
1877:
1847:
1811:
1778:
1748:
1726:
1711:. 7 May 2021.
1696:
1667:
1634:
1598:
1559:
1529:
1494:
1461:
1445:
1412:
1379:
1346:
1313:
1279:
1278:
1276:
1273:
1256:
1253:
1239:(CHMP) of the
1161:
1158:
1117:
1114:
1112:
1109:
1058:
1055:
1049:
1046:
998:
995:
883:(EGFR), HER2,
865:breast cancers
845:
844:
800:
798:
791:
785:
782:
771:cardiomyocytes
736:
733:
727:
724:
677:
674:
624:stomach cancer
618:used to treat
603:
602:
585:
584:
574:
568:
567:
564:
558:
552:
546:
540:
535:
529:
528:
524:
523:
513:
505:
504:
502:
501:
493:
491:
485:
484:
482:
481:
473:
471:
465:
464:
462:
461:
453:
451:
445:
444:
442:
441:
437:
435:
429:
428:
426:
425:
417:
415:
409:
408:
406:
405:
397:
395:
383:
382:
380:
379:
371:
369:
363:
362:
358:
357:
354:
345:
344:
341:
335:
334:
327:
326:
324:
323:
314:
299:
287:
273:
271:
265:
264:
260:
259:
257:
256:
243:
241:
235:
234:
229:
223:
222:
213:
211:administration
205:
204:
202:
201:
199:
189:
187:
179:
178:
176:
175:
157:
155:
149:
148:
141:
131:
130:
127:
121:
120:
117:
111:
110:
106:
105:
100:
94:
93:
83:
77:
76:
75:Whole antibody
73:
67:
66:
60:
59:
52:
26:
9:
6:
4:
3:
2:
10352:
10341:
10338:
10336:
10333:
10331:
10328:
10326:
10323:
10321:
10318:
10316:
10313:
10311:
10308:
10307:
10305:
10295:
10285:
10284:
10281:
10267:
10264:
10261:
10260:
10257:
10254:
10251:
10247:
10244:
10242:
10239:
10237:
10234:
10232:
10229:
10227:
10224:
10222:
10219:
10217:
10214:
10212:
10209:
10207:
10204:
10201:
10197:
10193:
10190:
10188:
10185:
10183:
10180:
10178:
10175:
10172:
10168:
10165:
10162:
10158:
10154:
10150:
10146:
10142:
10138:
10134:
10130:
10127:
10125:
10122:
10119:
10115:
10112:
10110:
10107:
10104:
10103:
10101:
10097:
10091:
10088:
10085:
10084:
10081:
10078:
10076:
10073:
10071:
10068:
10066:
10063:
10061:
10058:
10055:
10054:
10051:
10048:
10046:
10043:
10041:
10038:
10036:
10033:
10031:
10028:
10026:
10023:
10021:
10018:
10016:
10013:
10011:
10008:
10006:
10003:
10001:
9998:
9996:
9993:
9991:
9988:
9986:
9983:
9981:
9978:
9976:
9973:
9971:
9968:
9966:
9963:
9961:
9958:
9956:
9953:
9951:
9948:
9945:
9944:
9941:
9940:Cyclotraxin B
9938:
9935:
9934:
9930:
9926:
9922:
9918:
9914:
9911:
9909:
9906:
9904:
9901:
9899:
9896:
9893:
9892:
9890:
9888:
9884:
9874:
9871:
9869:
9866:
9864:
9861:
9859:
9856:
9854:
9853:Larotrectinib
9851:
9849:
9846:
9844:
9841:
9839:
9836:
9834:
9831:
9829:
9826:
9824:
9821:
9819:
9816:
9814:
9811:
9808:
9807:
9804:
9801:
9799:
9796:
9794:
9791:
9788:
9787:
9785:
9783:
9779:
9773:
9770:
9768:
9765:
9763:
9760:
9758:
9755:
9753:
9752:Larotrectinib
9750:
9748:
9745:
9743:
9740:
9738:
9735:
9733:
9730:
9728:
9725:
9723:
9720:
9718:
9715:
9713:
9710:
9707:
9706:
9703:
9700:
9697:
9696:
9693:
9690:
9688:
9687:Cyclotraxin B
9685:
9683:
9680:
9677:
9676:
9673:
9670:
9668:
9665:
9663:
9660:
9658:
9655:
9653:
9650:
9648:
9645:
9643:
9640:
9638:
9635:
9633:
9630:
9628:
9625:
9623:
9620:
9618:
9615:
9613:
9610:
9608:
9605:
9603:
9600:
9598:
9597:Amitriptyline
9595:
9593:
9590:
9588:
9585:
9583:
9580:
9578:
9575:
9573:
9570:
9568:
9565:
9563:
9560:
9557:
9556:
9554:
9552:
9548:
9542:
9539:
9536:
9535:
9532:
9529:
9526:
9523:
9522:
9519:
9516:
9514:
9511:
9509:
9506:
9504:
9501:
9499:
9496:
9494:
9491:
9489:
9486:
9484:
9481:
9477:
9474:
9473:Against TrkA:
9471:
9468:
9467:
9463:
9460:
9458:
9455:
9453:
9450:
9448:
9445:
9443:
9440:
9438:
9435:
9433:
9430:
9428:
9427:Larotrectinib
9425:
9423:
9420:
9418:
9415:
9413:
9410:
9408:
9405:
9403:
9400:
9398:
9395:
9393:
9390:
9388:
9385:
9382:
9381:
9378:
9375:
9372:
9371:
9368:
9365:
9363:
9360:
9358:
9357:Dexamethasone
9355:
9353:
9350:
9347:
9346:
9343:
9340:
9338:
9335:
9333:
9330:
9328:
9325:
9323:
9320:
9318:
9315:
9313:
9310:
9308:
9305:
9303:
9302:Amitriptyline
9300:
9297:
9296:
9294:
9292:
9288:
9285:
9283:
9279:
9272:
9268:
9267:
9265:
9263:
9259:
9253:
9250:
9248:
9245:
9243:
9240:
9238:
9235:
9233:
9230:
9228:
9225:
9223:
9220:
9218:
9215:
9213:
9210:
9208:
9205:
9203:
9200:
9197:
9196:
9193:
9190:
9188:
9185:
9182:
9181:
9179:
9177:
9173:
9163:
9160:
9157:
9156:
9154:
9150:
9144:
9141:
9138:
9137:
9134:
9131:
9128:
9127:
9125:
9123:
9119:
9113:
9110:
9107:
9106:
9103:
9100:
9097:
9096:
9094:
9092:
9088:
9082:
9079:
9076:
9075:
9072:
9069:
9066:
9065:
9063:
9061:
9057:
9051:
9048:
9045:
9044:
9041:
9038:
9036:
9033:
9030:
9029:
9027:
9025:
9021:
9018:
9016:
9012:
9006:
9003:
9001:
8998:
8996:
8993:
8990:
8989:
8986:
8983:
8981:
8978:
8976:
8973:
8971:
8968:
8966:
8963:
8961:
8958:
8956:
8953:
8951:
8948:
8946:
8943:
8941:
8938:
8936:
8933:
8931:
8928:
8926:
8923:
8921:
8918:
8916:
8913:
8911:
8908:
8905:
8904:
8900:
8896:
8892:
8888:
8884:
8881:
8879:
8876:
8873:
8872:
8870:
8868:
8864:
8858:
8855:
8852:
8851:
8848:
8845:
8842:
8839:
8838:
8835:
8832:
8830:
8827:
8825:
8822:
8820:
8817:
8815:
8812:
8810:
8807:
8805:
8802:
8800:
8797:
8794:
8791:
8790:
8787:
8784:
8782:
8779:
8777:
8776:Dexamethasone
8774:
8772:
8769:
8766:
8765:
8762:
8759:
8757:
8754:
8752:
8749:
8747:
8744:
8742:
8739:
8737:
8734:
8732:
8729:
8727:
8724:
8722:
8719:
8716:
8715:
8713:
8711:
8707:
8697:
8694:
8692:
8689:
8686:
8685:
8681:
8677:
8673:
8669:
8665:
8661:
8657:
8653:
8650:
8647:
8646:
8644:
8640:
8633:
8630:
8628:
8625:
8622:
8621:
8618:
8614:
8611:
8610:
8608:
8606:
8602:
8595:
8592:
8590:
8587:
8585:
8582:
8580:
8577:
8575:
8572:
8570:
8567:
8565:
8562:
8560:
8557:
8555:
8552:
8549:
8548:
8545:
8542:
8540:
8537:
8535:
8532:
8530:
8527:
8525:
8522:
8519:
8518:
8515:
8512:
8510:
8507:
8505:
8502:
8500:
8497:
8495:
8492:
8490:
8487:
8485:
8484:des(1-3)IGF-1
8481:
8478:
8477:
8475:
8473:
8469:
8466:
8464:
8460:
8454:
8451:
8449:
8448:Telisotuzumab
8446:
8444:
8441:
8439:
8436:
8434:
8431:
8429:
8426:
8424:
8421:
8418:
8417:
8414:
8411:
8409:
8406:
8404:
8401:
8399:
8396:
8394:
8391:
8389:
8386:
8384:
8381:
8379:
8376:
8374:
8371:
8369:
8366:
8364:
8361:
8359:
8356:
8354:
8351:
8349:
8346:
8344:
8341:
8339:
8336:
8334:
8331:
8329:
8326:
8324:
8321:
8319:
8316:
8313:
8312:
8309:
8306:
8305:Potentiators:
8303:
8302:
8299:
8296:
8294:
8290:
8287:
8286:
8284:
8282:
8278:
8268:
8265:
8262:
8261:
8259:
8255:
8249:
8246:
8243:
8239:
8235:
8231:
8227:
8223:
8219:
8215:
8212:
8210:
8207:
8204:
8203:
8201:
8199:
8195:
8188:
8185:
8182:
8181:
8178:
8175:
8173:
8170:
8168:
8167:Selpercatinib
8165:
8162:
8158:
8154:
8150:
8146:
8142:
8138:
8134:
8131:
8129:
8126:
8123:
8122:
8120:
8118:
8114:
8108:
8105:
8102:
8101:
8098:
8095:
8093:
8090:
8087:
8086:
8083:
8080:
8078:
8075:
8073:
8072:Selpercatinib
8070:
8068:
8065:
8063:
8060:
8057:
8053:
8049:
8045:
8041:
8037:
8033:
8029:
8025:
8021:
8017:
8013:
8009:
8005:
8001:
7998:
7996:
7993:
7990:
7989:
7987:
7985:
7981:
7975:
7972:
7970:
7967:
7965:
7964:Selpercatinib
7962:
7960:
7957:
7954:
7950:
7946:
7942:
7938:
7934:
7930:
7926:
7922:
7918:
7915:
7913:
7910:
7907:
7906:
7904:
7902:
7898:
7895:
7893:
7889:
7878:
7874:
7870:
7866:
7862:
7858:
7855:
7853:
7850:
7848:
7845:
7843:
7840:
7837:
7836:
7834:
7832:
7828:
7822:
7819:
7817:
7814:
7812:
7809:
7806:
7805:
7801:
7797:
7793:
7789:
7786:
7783:
7782:
7780:
7778:
7774:
7768:
7765:
7763:
7760:
7758:
7755:
7753:
7750:
7748:
7745:
7742:
7741:
7738:
7735:
7733:
7730:
7728:
7725:
7723:
7720:
7718:
7715:
7713:
7710:
7707:
7706:
7703:
7699:
7696:
7695:
7693:
7691:
7687:
7681:
7678:
7676:
7673:
7671:
7668:
7666:
7663:
7661:
7658:
7656:
7653:
7651:
7648:
7646:
7643:
7641:
7640:Depatuxizumab
7638:
7636:
7633:
7630:
7629:
7626:
7623:
7621:
7618:
7616:
7613:
7611:
7608:
7606:
7603:
7601:
7598:
7596:
7593:
7591:
7588:
7586:
7583:
7581:
7578:
7576:
7573:
7571:
7568:
7566:
7563:
7561:
7558:
7555:
7554:
7551:
7548:
7546:
7543:
7541:
7538:
7536:
7533:
7531:
7528:
7526:
7523:
7521:
7518:
7516:
7513:
7511:
7507:
7504:
7503:
7501:
7499:
7491:
7488:
7486:
7482:
7476:
7473:
7471:
7468:
7466:
7463:
7460:
7459:
7457:
7455:
7451:
7444:
7441:
7438:
7435:
7432:
7431:
7428:
7425:
7423:
7420:
7418:
7415:
7412:
7411:
7408:
7405:
7403:
7400:
7397:
7396:
7393:
7390:
7388:
7385:
7382:
7381:
7379:
7377:
7373:
7369:
7366:
7359:
7354:
7352:
7347:
7345:
7340:
7339:
7336:
7320:
7318:
7315:
7314:
7312:
7309:
7306:
7303:
7301:
7298:
7297:
7293:
7283:
7280:
7278:
7275:
7273:
7270:
7269:
7267:
7263:
7257:
7254:
7252:
7249:
7248:
7246:
7244:
7240:
7234:
7231:
7229:
7226:
7224:
7221:
7219:
7216:
7214:
7211:
7208:
7204:
7200:
7197:
7195:
7192:
7190:
7187:
7185:
7182:
7180:
7177:
7175:
7172:
7170:
7167:
7165:
7162:
7160:
7159:Rosmantuzumab
7157:
7155:
7152:
7150:
7147:
7145:
7142:
7140:
7137:
7135:
7132:
7130:
7127:
7125:
7122:
7120:
7117:
7115:
7112:
7110:
7107:
7105:
7102:
7100:
7097:
7095:
7092:
7090:
7087:
7085:
7082:
7080:
7077:
7075:
7072:
7070:
7067:
7065:
7062:
7060:
7057:
7055:
7052:
7050:
7047:
7045:
7042:
7040:
7037:
7035:
7032:
7030:
7027:
7025:
7022:
7020:
7017:
7015:
7014:Enoblituzumab
7012:
7010:
7007:
7005:
7002:
7000:
6997:
6995:
6992:
6990:
6987:
6985:
6982:
6980:
6977:
6975:
6972:
6970:
6967:
6965:
6962:
6960:
6957:
6955:
6952:
6950:
6947:
6945:
6942:
6940:
6937:
6935:
6932:
6930:
6927:
6925:
6922:
6920:
6917:
6915:
6912:
6911:
6909:
6907:
6903:
6897:
6894:
6892:
6889:
6887:
6884:
6882:
6879:
6877:
6874:
6872:
6869:
6867:
6864:
6862:
6859:
6857:
6854:
6852:
6849:
6847:
6844:
6842:
6839:
6837:
6834:
6832:
6829:
6827:
6824:
6822:
6819:
6817:
6814:
6812:
6809:
6807:
6804:
6802:
6799:
6798:
6796:
6794:
6790:
6784:
6781:
6779:
6776:
6774:
6771:
6769:
6766:
6764:
6761:
6759:
6756:
6754:
6751:
6749:
6746:
6744:
6741:
6739:
6736:
6734:
6731:
6729:
6726:
6724:
6721:
6719:
6716:
6714:
6711:
6709:
6706:
6704:
6701:
6699:
6696:
6694:
6691:
6689:
6686:
6684:
6681:
6679:
6676:
6674:
6671:
6669:
6666:
6664:
6661:
6659:
6656:
6654:
6651:
6650:
6648:
6644:
6638:
6635:
6633:
6630:
6628:
6625:
6623:
6620:
6618:
6615:
6613:
6610:
6608:
6605:
6603:
6600:
6598:
6595:
6593:
6590:
6588:
6585:
6583:
6580:
6578:
6575:
6573:
6570:
6568:
6567:Pembrolizumab
6565:
6563:
6560:
6558:
6555:
6553:
6550:
6548:
6545:
6543:
6540:
6538:
6535:
6533:
6530:
6528:
6525:
6523:
6520:
6518:
6515:
6513:
6510:
6508:
6505:
6503:
6500:
6498:
6495:
6493:
6490:
6488:
6485:
6483:
6480:
6478:
6475:
6473:
6470:
6468:
6465:
6463:
6460:
6458:
6455:
6453:
6450:
6448:
6445:
6443:
6440:
6438:
6435:
6433:
6430:
6428:
6425:
6423:
6420:
6418:
6415:
6412:
6408:
6405:
6403:
6402:Ascrinvacumab
6400:
6398:
6395:
6393:
6390:
6389:
6387:
6383:
6380:
6378:
6374:
6369:
6362:
6357:
6355:
6350:
6348:
6343:
6342:
6339:
6327:
6324:
6322:
6319:
6317:
6314:
6312:
6309:
6307:
6304:
6302:
6299:
6297:
6294:
6292:
6289:
6287:
6284:
6282:
6279:
6277:
6274:
6272:
6269:
6267:
6264:
6262:
6259:
6257:
6254:
6252:
6249:
6247:
6244:
6242:
6241:Larotrectinib
6239:
6237:
6234:
6232:
6229:
6227:
6224:
6222:
6219:
6217:
6214:
6210:
6207:
6205:
6202:
6200:
6197:
6195:
6192:
6190:
6187:
6186:
6185:
6182:
6178:
6175:
6173:
6170:
6169:
6168:
6166:
6162:
6158:
6155:
6153:
6150:
6148:
6145:
6143:
6140:
6138:
6135:
6134:
6133:
6132:
6128:
6124:
6121:
6119:
6116:
6114:
6111:
6110:
6109:
6107:
6103:
6099:
6096:
6094:
6093:Ridaforolimus
6091:
6089:
6086:
6085:
6084:
6083:
6079:
6076:
6072:
6071:
6067:
6063:
6060:
6056:
6055:
6051:
6047:
6043:
6040:
6036:
6035:
6031:
6027:
6026:
6024:
6020:
6008:
6005:
6003:
6002:Pirtobrutinib
6000:
5998:
5997:Orelabrutinib
5995:
5993:
5990:
5988:
5987:Acalabrutinib
5985:
5984:
5983:
5982:
5978:
5977:
5972:
5969:
5967:
5964:
5962:
5959:
5958:
5957:
5956:
5952:
5948:
5947:
5942:
5939:
5937:
5934:
5932:
5929:
5927:
5924:
5923:
5922:
5921:
5917:
5916:
5911:
5908:
5906:
5903:
5901:
5898:
5896:
5893:
5891:
5888:
5886:
5883:
5881:
5878:
5877:
5876:
5875:
5871:
5870:
5866:
5863:
5861:
5857:
5856:
5852:
5851:
5846:
5843:
5841:
5838:
5836:
5833:
5831:
5828:
5826:
5823:
5821:
5818:
5816:
5813:
5812:
5811:
5810:
5806:
5805:
5803:
5801:
5797:
5790:
5786:
5782:
5779:
5777:
5773:
5772:
5768:
5764:
5763:Selpercatinib
5760:
5759:Repotrectinib
5756:
5752:
5748:
5747:Larotrectinib
5744:
5740:
5736:
5733:
5731:
5727:
5726:
5721:
5718:
5716:
5713:
5711:
5708:
5707:
5706:
5705:
5701:
5700:
5695:
5692:
5690:
5687:
5685:
5682:
5680:
5677:
5675:
5672:
5670:
5667:
5665:
5662:
5660:
5657:
5655:
5652:
5650:
5647:
5645:
5642:
5640:
5637:
5635:
5632:
5631:
5630:
5629:
5625:
5624:
5620:
5616:
5612:
5611:
5607:
5604:
5601:
5599:
5596:
5594:
5591:
5589:
5586:
5584:
5581:
5579:
5576:
5574:
5571:
5569:
5565:
5564:
5560:
5555:
5554:RTK class III
5552:
5551:
5546:
5543:
5541:
5538:
5536:
5533:
5532:
5531:
5530:
5525:
5524:
5520:
5517:
5515:
5512:
5510:
5507:
5505:
5502:
5500:
5497:
5495:
5492:
5490:
5487:
5485:
5482:
5480:
5477:
5475:
5472:
5470:
5467:
5465:
5462:
5460:
5456:
5455:
5450:
5447:
5446:
5444:
5442:
5438:
5435:
5432:
5428:
5418:
5415:
5413:
5410:
5408:
5405:
5403:
5400:
5398:
5395:
5393:
5390:
5388:
5385:
5383:
5380:
5378:
5375:
5373:
5370:
5368:
5365:
5363:
5360:
5358:
5355:
5353:
5350:
5348:
5345:
5343:
5340:
5338:
5337:Pembrolizumab
5335:
5333:
5330:
5328:
5325:
5323:
5320:
5318:
5315:
5313:
5310:
5308:
5305:
5303:
5302:Mogamulizumab
5300:
5298:
5295:
5293:
5290:
5288:
5285:
5283:
5280:
5278:
5275:
5273:
5270:
5268:
5265:
5263:
5260:
5258:
5255:
5253:
5250:
5248:
5245:
5243:
5240:
5238:
5235:
5233:
5230:
5228:
5225:
5223:
5220:
5218:
5215:
5213:
5210:
5207:
5203:
5200:
5198:
5195:
5194:
5192:
5188:
5181:
5177:
5176:
5171:
5168:
5167:
5163:
5159:
5158:
5153:
5149:
5148:
5143:
5140:
5138:
5135:
5133:
5130:
5128:
5125:
5123:
5122:Mosunetuzumab
5120:
5118:
5115:
5113:
5109:
5108:
5103:
5102:Mosunetuzumab
5099:
5095:
5091:
5090:
5085:
5082:
5081:
5079:
5077:
5073:
5069:
5062:
5058:
5057:
5053:
5050:
5047:
5045:
5041:
5040:
5036:
5035:
5033:
5029:
5022:
5019:
5017:
5014:
5011:
5007:
5003:
4999:
4998:
4994:
4991:
4988:
4986:
4982:
4981:
4976:
4973:
4972:
4970:
4968:
4964:
4961:
4958:
4955:
4951:
4946:
4942:
4938:
4931:
4926:
4924:
4919:
4917:
4912:
4911:
4908:
4900:
4896:
4895:"Trastuzumab"
4892:
4891:
4873:
4869:
4865:
4861:
4857:
4856:
4851:
4846:
4842:
4838:
4833:
4828:
4824:
4820:
4816:
4812:
4808:
4803:
4791:
4787:
4786:
4781:
4776:
4772:
4770:0-679-45702-X
4766:
4762:
4757:
4756:
4735:
4731:
4727:
4721:
4705:
4701:
4699:
4693:
4687:
4671:
4667:
4663:
4657:
4640:
4636:
4635:"Tuznue EPAR"
4630:
4628:
4626:
4608:
4604:
4600:
4594:
4592:
4575:
4571:
4570:Health Canada
4567:
4561:
4545:
4541:
4540:Health Canada
4537:
4531:
4515:
4511:
4510:Health Canada
4507:
4501:
4485:
4481:
4480:Health Canada
4477:
4471:
4455:
4451:
4449:
4444:
4438:
4422:
4418:
4416:
4411:
4405:
4398:
4397:public domain
4379:
4375:
4373:
4367:
4361:
4359:
4357:
4340:
4336:
4334:
4328:
4322:
4306:
4302:
4300:
4295:
4289:
4273:
4269:
4263:
4247:
4243:
4241:
4236:
4230:
4214:
4210:
4204:
4197:
4196:public domain
4178:
4174:
4172:
4166:
4160:
4144:
4140:
4136:
4130:
4122:
4116:
4100:
4096:
4089:
4073:
4069:
4065:
4061:
4054:
4038:
4034:
4033:
4028:
4021:
4005:
4001:
3997:
3993:
3989:
3982:
3966:
3962:
3958:
3952:
3936:
3932:
3925:
3909:
3905:
3899:
3891:
3887:
3883:
3879:
3875:
3871:
3867:
3863:
3856:
3848:
3844:
3840:
3833:
3817:
3813:
3812:
3807:
3800:
3784:
3780:
3776:
3770:
3762:
3758:
3753:
3748:
3743:
3738:
3734:
3730:
3726:
3722:
3718:
3711:
3703:
3699:
3695:
3691:
3687:
3683:
3679:
3675:
3671:
3667:
3660:
3644:
3640:
3634:
3626:
3622:
3617:
3612:
3608:
3604:
3600:
3596:
3592:
3588:
3584:
3577:
3561:
3557:
3551:
3535:
3531:
3525:
3509:
3505:
3499:
3497:
3480:
3476:
3470:
3462:
3458:
3453:
3448:
3444:
3440:
3436:
3432:
3428:
3424:
3420:
3413:
3405:
3401:
3396:
3391:
3387:
3383:
3379:
3375:
3371:
3364:
3356:
3352:
3348:
3344:
3340:
3339:10.1038/74704
3336:
3332:
3328:
3321:
3313:
3309:
3305:
3299:
3295:
3291:
3287:
3280:
3272:
3268:
3264:
3260:
3256:
3252:
3248:
3244:
3240:
3236:
3229:
3221:
3217:
3213:
3209:
3205:
3201:
3197:
3193:
3189:
3185:
3178:
3170:
3166:
3161:
3156:
3152:
3148:
3144:
3137:
3121:
3117:
3113:
3106:
3098:
3094:
3090:
3086:
3082:
3078:
3074:
3070:
3063:
3047:
3043:
3039:
3033:
3031:
3022:
3018:
3014:
3010:
3006:
3005:10.1038/87872
3002:
2998:
2994:
2987:
2968:
2961:
2955:
2947:
2943:
2938:
2933:
2929:
2925:
2921:
2914:
2906:
2902:
2898:
2894:
2890:
2886:
2882:
2878:
2871:
2863:
2859:
2855:
2851:
2847:
2843:
2836:
2817:
2810:
2804:
2802:
2785:
2781:
2775:
2767:
2763:
2759:
2755:
2748:
2740:
2736:
2732:
2728:
2723:
2718:
2714:
2710:
2706:
2699:
2691:
2687:
2683:
2679:
2674:
2669:
2665:
2661:
2657:
2653:
2646:
2638:
2634:
2630:
2626:
2621:
2616:
2612:
2608:
2604:
2597:
2590:
2589:public domain
2571:
2567:
2565:
2559:
2553:
2545:
2541:
2537:
2533:
2528:
2523:
2519:
2515:
2511:
2504:
2502:
2500:
2491:
2487:
2482:
2477:
2473:
2469:
2465:
2458:
2456:
2454:
2445:
2441:
2436:
2431:
2427:
2423:
2419:
2412:
2404:
2400:
2396:
2392:
2385:
2377:
2373:
2369:
2365:
2361:
2357:
2353:
2346:
2338:
2334:
2329:
2324:
2320:
2316:
2312:
2308:
2304:
2297:
2289:
2285:
2281:
2277:
2273:
2269:
2262:
2260:
2251:
2247:
2242:
2237:
2233:
2229:
2225:
2221:
2217:
2210:
2208:
2206:
2197:
2193:
2188:
2183:
2179:
2175:
2171:
2167:
2163:
2156:
2137:
2133:
2129:
2124:
2119:
2115:
2111:
2107:
2103:
2096:
2089:
2080:
2075:
2071:
2067:
2061:
2054:
2053:public domain
2035:
2031:
2029:
2023:
2017:
2015:
2006:
2000:
1996:
1990:
1974:
1970:
1968:
1963:
1957:
1955:
1938:
1934:
1932:
1926:
1920:
1904:
1900:
1899:"Trastuzumab"
1894:
1892:
1890:
1888:
1886:
1884:
1882:
1865:
1861:
1857:
1851:
1835:
1831:
1829:
1824:
1823:"Ogivri EPAR"
1818:
1816:
1799:
1795:
1791:
1785:
1783:
1766:
1762:
1761:Health Canada
1758:
1752:
1744:
1740:
1736:
1735:"Trastuzumab"
1730:
1714:
1710:
1706:
1700:
1685:
1681:
1677:
1671:
1655:
1651:
1647:
1641:
1639:
1622:
1618:
1616:
1611:
1605:
1603:
1586:
1582:
1578:
1572:
1570:
1568:
1566:
1564:
1547:
1543:
1539:
1533:
1517:
1513:
1509:
1503:
1501:
1499:
1482:
1478:
1474:
1468:
1466:
1459:
1454:
1452:
1450:
1433:
1429:
1425:
1419:
1417:
1400:
1396:
1392:
1386:
1384:
1367:
1363:
1359:
1353:
1351:
1334:
1330:
1326:
1320:
1318:
1301:
1297:
1296:www.drugs.com
1293:
1287:
1285:
1280:
1272:
1270:
1266:
1262:
1252:
1248:
1245:
1242:
1238:
1233:
1230:
1227:
1224:
1221:
1218:
1215:
1212:
1209:
1205:
1203:
1198:
1194:
1193:were lifted.
1192:
1188:
1184:
1179:
1177:
1173:
1167:
1157:
1154:
1149:
1142:
1140:
1135:
1133:
1128:
1125:
1108:
1105:
1100:
1098:
1094:
1090:
1086:
1085:
1080:
1079:Dennis Slamon
1076:
1072:
1068:
1064:
1054:
1045:
1043:
1039:
1035:
1033:
1028:
1026:
1022:
1017:
1013:
1009:
1005:
994:
992:
987:
985:
980:
976:
970:
968:
964:
959:
957:
956:cell motility
953:
949:
945:
941:
937:
933:
929:
925:
921:
917:
913:
908:
906:
902:
897:
894:
890:
886:
882:
876:
874:
870:
866:
862:
858:
854:
853:
841:
838:
830:
820:
815:
811:
807:
806:
799:
790:
789:
781:
778:
776:
772:
768:
763:
761:
757:
753:
748:
746:
742:
732:
723:
721:
717:
713:
712:pembrolizumab
708:
704:
700:
696:
694:
693:relative risk
690:
685:
683:
673:
671:
666:
664:
663:HER2 receptor
660:
657:. Use during
656:
652:
648:
647:heart failure
643:
641:
637:
633:
629:
625:
621:
620:breast cancer
617:
613:
609:
599:
592:
586:
575:
573:
569:
536:
534:
530:
525:
521:
517:
514:
512:
510:ECHA InfoCard
506:
499:
498:ChEMBL1201585
495:
494:
492:
490:
486:
479:
475:
474:
472:
470:
466:
459:
455:
454:
452:
450:
446:
439:
438:
436:
434:
430:
423:
419:
418:
416:
414:
410:
403:
399:
398:
396:
388:
384:
377:
373:
372:
370:
368:
364:
359:
355:
353:
346:
342:
340:
336:
332:
328:
322: Rx-only
315:
312:
300:
297:
288:
285:
275:
274:
272:
270:
266:
261:
253:
248:
245:
244:
242:
240:
236:
233:
230:
228:
224:
221:
217:
214:
212:
206:
200:
191:
190:
188:
186:
180:
173:
168:
159:
158:
156:
154:
150:
146:
142:
140:
136:
132:
128:
126:
122:
118:
116:
112:
109:Clinical data
107:
104:
101:
99:
95:
91:
87:
84:
82:
78:
74:
72:
68:
65:
61:
56:
50:
45:
37:
33:
19:
10266:Cerebrolysin
10262:
10236:Pleiotrophin
10192:Interleukins
10105:
10086:
10056:
9975:Fruquintinib
9965:Cabozantinib
9946:
9936:
9894:
9858:Lestaurtinib
9809:
9789:
9757:Lestaurtinib
9708:
9698:
9679:Antagonists:
9678:
9612:Deoxygedunin
9567:3,7,8,2'-THF
9558:
9537:
9528:Against NGF:
9527:
9524:
9480:Against NGF:
9479:
9472:
9469:
9432:Lestaurtinib
9383:
9373:
9367:Testosterone
9349:Antagonists:
9348:
9298:
9198:
9183:
9158:
9139:
9129:
9108:
9098:
9077:
9067:
9046:
9031:
8991:
8906:
8874:
8853:
8844:Against NGF:
8843:
8840:
8796:Against NGF:
8795:
8792:
8786:Testosterone
8768:Antagonists:
8767:
8717:
8687:
8648:
8623:
8612:
8589:Teprotumumab
8550:
8520:
8479:
8428:Ficlatuzumab
8423:Emibetuzumab
8419:
8373:JNJ-38877605
8343:Cabozantinib
8314:
8304:
8293:Fosgonimeton
8288:
8263:
8205:
8183:
8124:
8107:Infigratinib
8103:
8088:
7991:
7908:
7842:Betacellulin
7838:
7821:Seribantumab
7807:
7784:
7743:
7721:
7708:
7702:Unknown/none
7701:
7697:
7631:
7556:
7515:Betacellulin
7510:Amphiregulin
7505:
7497:(ErbB1/HER1)
7461:
7433:
7413:
7399:Antagonists:
7398:
7383:
7376:Angiopoietin
7198:
7174:Sibrotuzumab
7139:Parsatuzumab
7124:Otlertuzumab
7119:Odronextamab
7114:Ocaratuzumab
7109:Obinutuzumab
7084:Lumretuzumab
7039:Flotetuzumab
7034:Ficlatuzumab
7029:Farletuzumab
7024:Etaracizumab
7009:Emibetuzumab
6896:Zolbetuximab
6871:Margetuximab
6851:Girentuximab
6713:Minretumomab
6678:Blinatumomab
6617:Teprotumumab
6597:Seribantumab
6422:Botensilimab
6407:Atezolizumab
6392:Adecatumumab
6281:Pexidartinib
6266:Odronextamab
6236:Gilteritinib
6216:Cabozantinib
6163:
6129:
6104:
6098:Temsirolimus
6080:
6064:
6046:proapoptotic
6044:
6028:
6007:Zanubrutinib
5979:
5949:
5918:
5895:Lestaurtinib
5874:Janus kinase
5872:
5853:
5807:
5800:Non-receptor
5781:Cabozantinib
5774:
5743:Infigratinib
5728:
5702:
5644:Fruquintinib
5626:
5619:Gilteritinib
5615:Lestaurtinib
5608:
5557:
5526:
5499:Mobocertinib
5464:Aumolertinib
5452:
5417:Tremelimumab
5402:Tislelizumab
5357:Retifanlimab
5232:Blinatumomab
5202:Atezolizumab
5173:
5155:
5145:
5127:Obinutuzumab
5105:
5087:
5054:
5037:
5005:
4995:
4978:
4898:
4876:. Retrieved
4854:
4817:(4): 25–35.
4814:
4810:
4794:. Retrieved
4785:The Guardian
4783:
4760:
4738:. Retrieved
4729:
4720:
4708:. Retrieved
4695:
4686:
4674:. Retrieved
4665:
4656:
4643:. Retrieved
4638:
4613:21 September
4611:. Retrieved
4602:
4578:. Retrieved
4569:
4560:
4548:. Retrieved
4539:
4530:
4518:. Retrieved
4509:
4500:
4488:. Retrieved
4479:
4470:
4458:. Retrieved
4446:
4437:
4425:. Retrieved
4413:
4404:
4382:. Retrieved
4369:
4343:. Retrieved
4330:
4321:
4309:. Retrieved
4297:
4288:
4276:. Retrieved
4262:
4250:. Retrieved
4238:
4229:
4217:. Retrieved
4203:
4181:. Retrieved
4168:
4159:
4147:. Retrieved
4143:the original
4138:
4129:
4103:. Retrieved
4098:
4088:
4076:. Retrieved
4067:
4063:
4053:
4041:. Retrieved
4030:
4020:
4008:. Retrieved
3991:
3981:
3969:. Retrieved
3960:
3951:
3939:. Retrieved
3924:
3912:. Retrieved
3908:the original
3898:
3868:(3): 13–17.
3865:
3861:
3855:
3843:FiercePharma
3842:
3832:
3820:. Retrieved
3809:
3799:
3787:. Retrieved
3769:
3724:
3720:
3710:
3669:
3665:
3659:
3647:. Retrieved
3633:
3590:
3586:
3576:
3564:. Retrieved
3550:
3538:. Retrieved
3534:the original
3524:
3512:. Retrieved
3483:. Retrieved
3469:
3426:
3422:
3412:
3377:
3373:
3363:
3330:
3326:
3320:
3285:
3279:
3238:
3234:
3228:
3187:
3183:
3177:
3150:
3146:
3136:
3124:. Retrieved
3115:
3105:
3072:
3068:
3062:
3050:. Retrieved
3041:
2996:
2992:
2986:
2974:. Retrieved
2954:
2927:
2923:
2913:
2880:
2876:
2870:
2845:
2841:
2835:
2823:. Retrieved
2788:. Retrieved
2774:
2757:
2753:
2747:
2712:
2708:
2698:
2673:10722/251817
2655:
2651:
2645:
2610:
2606:
2596:
2574:. Retrieved
2561:
2552:
2520:(2): 86–93.
2517:
2513:
2474:(1): 87–95.
2471:
2467:
2425:
2421:
2411:
2394:
2390:
2384:
2359:
2355:
2345:
2310:
2306:
2296:
2274:(1): 39–51.
2271:
2267:
2223:
2219:
2169:
2165:
2155:
2143:. Retrieved
2105:
2101:
2088:
2079:10665/371090
2069:
2060:
2038:. Retrieved
2034:the original
2025:
1994:
1989:
1977:. Retrieved
1965:
1941:. Retrieved
1928:
1919:
1907:. Retrieved
1868:. Retrieved
1859:
1850:
1838:. Retrieved
1826:
1802:. Retrieved
1793:
1769:. Retrieved
1760:
1751:
1743:the original
1738:
1729:
1717:. Retrieved
1708:
1699:
1687:. Retrieved
1679:
1670:
1658:. Retrieved
1649:
1625:. Retrieved
1613:
1589:. Retrieved
1580:
1550:. Retrieved
1541:
1532:
1520:. Retrieved
1511:
1485:. Retrieved
1476:
1436:. Retrieved
1427:
1403:. Retrieved
1394:
1370:. Retrieved
1361:
1337:. Retrieved
1328:
1304:. Retrieved
1295:
1258:
1249:
1246:
1234:
1231:
1228:
1225:
1222:
1219:
1216:
1213:
1210:
1206:
1199:
1195:
1180:
1169:
1150:
1143:
1136:
1129:
1126:
1119:
1101:
1097:Fast-tracked
1084:Living Proof
1082:
1073:oncogene by
1070:
1063:Axel Ullrich
1060:
1051:
1036:
1029:
1024:
1000:
988:
979:angiogenesis
971:
960:
932:angiogenesis
909:
898:
877:
860:
856:
850:
848:
833:
827:October 2016
824:
817:Please help
813:
802:
779:
767:neuregulin-1
764:
749:
738:
729:
709:
705:
701:
697:
689:Hazard ratio
686:
679:
676:Medical uses
667:
655:lung disease
644:
611:
607:
606:
595:
589:
349:Elimination
269:Legal status
263:Legal status
220:subcutaneous
153:License data
53:Trastuzumab
36:
10226:Oncomodulin
10090:Aflibercept
10080:Ranibizumab
10075:Ramucirumab
10065:Bevacizumab
10057:Antibodies:
10015:Regorafenib
9955:Altiratinib
9868:ONO-5390556
9838:Entrectinib
9813:Altiratinib
9767:ONO-5390556
9737:Entrectinib
9712:Altiratinib
9498:Frunevetmab
9470:Antibodies:
9447:ONO-5390556
9412:Entrectinib
9387:Altiratinib
9342:Tavilermide
9237:Quizartinib
9176:SCF (c-Kit)
9000:Ramucirumab
8992:Antibodies:
8965:Quizartinib
8915:Avapritinib
8878:Becaplermin
8814:Frunevetmab
8793:Antibodies:
8696:Trofinetide
8627:Dusigitumab
8624:Antibodies:
8579:Robatumumab
8569:Figitumumab
8564:Dalotuzumab
8559:Cixutumumab
8551:Antibodies:
8443:Rilotumumab
8438:Onartuzumab
8433:Flanvotumab
8420:Antibodies:
8388:PF-04217903
8318:Altiratinib
8281:HGF (c-Met)
8184:Antibodies:
8089:Antibodies:
7811:Duligotumab
7808:Antibodies:
7722:Trastuzumab
7712:Ertumaxomab
7709:Antibodies:
7680:Zalutumumab
7675:Panitumumab
7670:Nimotuzumab
7665:Necitumumab
7655:Imgatuzumab
7632:Antibodies:
7615:Osimertinib
7580:Dacomitinib
7475:Dapiclermin
7434:Antibodies:
7417:Altiratinib
7307:from market
7282:Ontuxizumab
7256:Ertumaxomab
7251:Catumaxomab
7223:Vanucizumab
7203:+deruxtecan
7199:Trastuzumab
7194:Tigatuzumab
7129:Onartuzumab
7104:Nimotuzumab
7094:Milatuzumab
7064:Labetuzumab
7054:Imgatuzumab
7019:Epcoritamab
7004:Emactuzumab
6989:Dalotuzumab
6979:Dacetuzumab
6959:Cirmtuzumab
6934:Bevacizumab
6919:Alemtuzumab
6891:Ublituximab
6841:Ensituximab
6836:Ecromeximab
6831:Dinutuximab
6816:Carotuximab
6806:Bavituximab
6783:Tositumomab
6778:Tenatumomab
6748:Racotumomab
6693:Edrecolomab
6668:Arcitumomab
6637:Zalutumumab
6627:Vantictumab
6602:Sugemalimab
6592:Robatumumab
6587:Rilotumumab
6582:Ramucirumab
6557:Panitumumab
6532:Necitumumab
6522:Mapatumumab
6517:Lucatumumab
6512:Lexatumumab
6502:Istiratumab
6487:Intetumumab
6472:Flanvotumab
6467:Figitumumab
6452:Dusigitumab
6447:Duligotumab
6437:Daratumumab
6432:Conatumumab
6427:Cixutumumab
6417:Balstilimab
6397:Amivantamab
6311:Tebentafusp
6291:Regorafenib
6286:Quizartinib
6276:Pemigatinib
6256:Midostaurin
6231:Erdafitinib
6226:Entrectinib
6209:Parsaclisib
6157:Trilaciclib
6147:Palbociclib
6142:Dalpiciclib
6137:Abemaciclib
6039:Aflibercept
5966:Entrectinib
5936:Selumetinib
5931:Cobimetinib
5926:Binimetinib
5910:Ruxolitinib
5900:Momelotinib
5880:Baricitinib
5778:inhibitors:
5755:Pralsetinib
5751:Pemigatinib
5739:Futibatinib
5735:Entrectinib
5732:inhibitors:
5664:Regorafenib
5568:Avapritinib
5514:Rociletinib
5509:Osimertinib
5474:Dacomitinib
5412:Toripalimab
5397:Teclistamab
5387:Talquetamab
5382:Tafasitamab
5377:Sugemalimab
5372:Serplulimab
5362:Sabatolimab
5352:Ramucirumab
5347:Prolgolimab
5317:Necitumumab
5272:Epcoritamab
5252:Dostarlimab
5242:Daratumumab
5197:Amivantamab
5162:Alemtuzumab
5152:Brentuximab
5142:Tositumomab
5117:Ibritumomab
5098:Elranatamab
5061:Bevacizumab
5049:Edrecolomab
5044:Catumaxomab
5006:Trastuzumab
4990:Panitumumab
4796:13 December
4740:11 December
4710:20 December
4676:11 December
4384:12 December
4219:26 December
2930:(3): 70–4.
1943:18 February
1870:11 December
1552:11 December
1522:11 December
1487:11 December
1438:11 December
1405:11 December
1372:11 December
1339:11 December
1306:21 December
1166:Biosimilars
1160:Biosimilars
821:if you can.
608:Trastuzumab
583: g·mol
516:100.224.377
376:180288-69-1
361:Identifiers
216:Intravenous
172:Trastuzumab
125:Biosimilars
115:Trade names
41:Trastuzumab
10320:Immunology
10304:Categories
10045:Vandetanib
10010:Rebastinib
10005:Pegaptanib
9995:Nintedanib
9985:Lenvatinib
9950:Agerafenib
9903:Ripretinib
9828:CH-7057288
9727:CH-7057288
9592:7,8,3'-THF
9587:7,8,2'-THF
9513:Ranevetmab
9503:Fulranumab
9457:Rebastinib
9402:CH-7057288
9317:Cenegermin
9202:Agerafenib
9162:Agerafenib
9143:Vandetanib
9112:Vandetanib
9081:Vandetanib
9050:Vandetanib
8995:Olaratumab
8970:Ripretinib
8950:Nintedanib
8935:Lenvatinib
8925:Crenolanib
8910:Agerafenib
8829:Ranevetmab
8819:Fulranumab
8736:Cenegermin
8710:LNGF (p75)
8632:Xentuzumab
8594:Xentuzumab
8539:NVP-AEW541
8534:NVP-ADW742
8529:Linsitinib
8524:BMS-754807
8509:Mecasermin
8408:Tivantinib
8398:PHA-665752
8393:PF-2341066
8363:Golvatinib
8353:Crizotinib
8348:Capmatinib
8338:BMS-777607
8333:Amuvatinib
8209:Ersofermin
8172:Sprifermin
8128:Ersofermin
8077:Sprifermin
8067:Repifermin
8062:Palifermin
7995:Ersofermin
7974:Velafermin
7959:Repifermin
7912:Ersofermin
7831:ErbB4/HER4
7816:Patritumab
7777:ErbB3/HER3
7757:Mubritinib
7717:Pertuzumab
7690:ErbB2/HER2
7620:Vandetanib
7575:Canertinib
7570:Brigatinib
7565:Agerafenib
7545:Nepidermin
7540:Murodermin
7530:Epiregulin
7485:EGF (ErbB)
7443:Nesvacumab
7437:Evinacumab
7427:Rebastinib
7368:modulators
7228:Veltuzumab
7207:+emtansine
7179:Simtuzumab
7144:Pertuzumab
7074:Lintuzumab
7049:Glofitamab
6999:Elotuzumab
6984:Demcizumab
6924:Axatilimab
6914:Abituzumab
6886:Siltuximab
6861:Isatuximab
6801:Amatuximab
6773:Pintumomab
6743:Pemtumomab
6738:Oregovomab
6673:Bectumomab
6653:Abagovomab
6607:Tarextumab
6577:Radretumab
6572:Pritumumab
6562:Patritumab
6552:Olaratumab
6547:Ofatumumab
6537:Nesvacumab
6527:Narnatumab
6497:Iratumumab
6492:Ipilimumab
6462:Enoticumab
6442:Drozitumab
6370:for tumors
6326:Venetoclax
6321:Vandetanib
6296:Ripretinib
6261:Nintedanib
6246:Lenvatinib
6221:Capmatinib
6204:Idelalisib
6194:Copanlisib
6167:inhibitors
6152:Ribociclib
6123:Vismodegib
6108:inhibitors
6088:Everolimus
6054:prohibitin
5971:Lorlatinib
5961:Crizotinib
5941:Trametinib
5905:Pacritinib
5890:Filgotinib
5885:Fedratinib
5789:Crizotinib
5785:Capmatinib
5767:Vandetanib
5715:Brigatinib
5694:Vandetanib
5654:Nintedanib
5649:Lenvatinib
5588:Ripretinib
5519:Vandetanib
5494:Lazertinib
5469:Brigatinib
5392:Tarlatamab
5327:Olaratumab
5287:Isatuximab
5282:Ipilimumab
5262:Elotuzumab
5257:Durvalumab
5237:Cemiplimab
5227:Bermekimab
5217:Axatilimab
5132:Ofatumumab
5112:Glofitamab
5094:Glofitamab
5002:Pertuzumab
4878:5 February
4278:18 January
4183:2 December
4043:26 October
4010:4 February
3941:20 October
2976:22 October
2825:22 October
2468:Cell Cycle
2040:3 December
1909:8 December
1689:22 October
1660:3 December
1275:References
1263:, such as
1176:biosimilar
1164:See also:
1122:US$ 70,000
1048:Resistance
975:cell cycle
893:MAP kinase
572:Molar mass
458:P188ANX8CK
433:ChemSpider
367:CAS Number
339:Metabolism
227:Drug class
55:Fab region
27:Medication
10070:Icrucumab
10050:WHI-P 154
10040:Tivozanib
10035:Toceranib
10030:Sunitinib
10025:Sorafenib
10020:Semaxanib
10000:Pazopanib
9990:Motesanib
9980:Lapatinib
9970:Cediranib
9908:Telbermin
9895:Agonists:
9843:GZ-389988
9823:CE-245677
9790:Agonists:
9742:GZ-389988
9722:CE-245677
9622:Diosmetin
9559:Agonists:
9525:Aptamers:
9518:Tanezumab
9493:Fasinumab
9437:Milciclib
9417:GZ-389988
9397:CE-245677
9299:Agonists:
9252:Toceranib
9247:Sunitinib
9242:Sorafenib
9232:Pazopanib
9227:Nilotinib
9222:Masitinib
9212:Dasatinib
9184:Agonists:
9130:Agonists:
9099:Agonists:
9068:Agonists:
9040:Liatermin
9032:Agonists:
9015:RET (GFL)
9005:Tovetumab
8985:Toceranib
8980:Sorafenib
8975:Sunitinib
8960:Radotinib
8955:Pazopanib
8945:Motesanib
8940:Masitinib
8875:Agonists:
8841:Aptamers:
8834:Tanezumab
8809:Fasinumab
8718:Agonists:
8574:Ganitumab
8494:IGF-1 LR3
8413:Volitinib
8368:INCB28060
8358:Foretinib
8264:Agonists:
8248:Trafermin
8206:Agonists:
8187:Burosumab
8177:Trafermin
8125:Agonists:
8092:Aprutumab
8082:Trafermin
8044:10 (KGF2)
7992:Agonists:
7969:Trafermin
7949:10 (KGF2)
7909:Agonists:
7839:Agonists:
7785:Agonists:
7767:Tucatinib
7762:Neratinib
7752:Lapatinib
7660:Matuzumab
7650:Futuximab
7635:Cetuximab
7625:WHI-P 154
7610:Neratinib
7605:Lapatinib
7595:Grandinin
7590:Gefitinib
7585:Erlotinib
7462:Agonists:
7422:CE-245677
7384:Agonists:
7317:Phase III
7305:Withdrawn
7099:Naxitamab
7089:Matuzumab
6906:Humanized
6881:Rituximab
6846:Futuximab
6821:Cetuximab
6758:Solitomab
6718:Mitumomab
6708:Lilotomab
6688:Detumomab
6632:Votumumab
6622:Tovetumab
6542:Nivolumab
6507:Icrucumab
6477:Ganitumab
6316:Tepotinib
6306:Sunitinib
6301:Sorafenib
6271:Pazopanib
6251:Masitinib
6199:Duvelisib
6189:Alpelisib
6177:Sotorasib
6172:Adagrasib
6118:Sonidegib
6113:Glasdegib
6059:Adipotide
5992:Ibrutinib
5865:Dasatinib
5860:Bosutinib
5845:Radotinib
5840:Ponatinib
5835:Nilotinib
5825:Dasatinib
5820:Bosutinib
5815:Asciminib
5783:(VEGFR),
5741:(FGFR2),
5720:Ceritinib
5710:Alectinib
5689:Toceranib
5684:Tivozanib
5679:Sunitinib
5674:Sorafenib
5669:Semaxanib
5659:Pazopanib
5639:Cediranib
5603:Toceranib
5598:Sunitinib
5593:Sorafenib
5583:Pazopanib
5578:Masitinib
5545:Tucatinib
5540:Neratinib
5535:Lapatinib
5504:Olmutinib
5484:Gefitinib
5479:Erlotinib
5454:HER1/EGFR
5322:Nivolumab
5312:Naxitamab
5137:Rituximab
4985:Cetuximab
4980:HER1/EGFR
4000:0013-0389
3779:Genentech
3566:6 January
3540:6 January
3110:Winer E.
1719:8 January
1650:Drugs.com
1187:AryoTrust
1116:Economics
1089:Genentech
1034:Pathway.
756:MUGA scan
682:lapatinib
659:pregnancy
612:Herceptin
356:2-12 days
351:half-life
209:Routes of
183:Pregnancy
145:Monograph
139:Drugs.com
86:Humanized
18:Herceptin
10294:Medicine
10252:instead)
10241:Renalase
10202:instead)
10173:instead)
10120:instead)
9960:Axitinib
9929:D (FIGF)
9873:PLX-7486
9863:ONO-4474
9818:AZD-6918
9772:PLX-7486
9762:ONO-4474
9717:AZD-6918
9699:Ligands:
9617:Deprenyl
9577:7,3'-DHF
9508:MEDI-578
9488:ASP-6294
9452:PLX-7486
9442:ONO-4474
9392:AZD-6918
9352:ALE-0540
9273:instead.
9217:Imatinib
9207:Axitinib
9187:Ancestim
9152:Unsorted
8930:Imatinib
8920:Axitinib
8824:MEDI-578
8804:ASP-6294
8771:ALE-0540
8613:Agonists
8554:AVE-1642
8480:Agonists
8403:SU-11274
8289:Agonists
8267:FGF15/19
8257:Unsorted
8222:2 (bFGF)
8141:2 (bFGF)
8008:2 (bFGF)
7925:2 (bFGF)
7747:Afatinib
7698:Agonists
7600:Icotinib
7560:Afatinib
7506:Agonists
6793:Chimeric
6703:Igovomab
6106:hedgehog
6068:against
6066:exotoxin
6032:against
5981:Bruton's
5830:Imatinib
5753:(FGFR),
5749:(NTRK),
5634:Axitinib
5573:Axitinib
5529:HER2/neu
5489:Icotinib
5459:Afatinib
5433:("-nib")
5212:Avelumab
5084:lymphoid
5076:lymphoma
5072:Leukemia
4997:HER2/neu
4959:("-mab")
4872:Archived
4868:28520362
4862:(NCBI).
4841:19672422
4790:Archived
4734:Archived
4704:Archived
4670:Archived
4607:Archived
4574:Archived
4544:Archived
4514:Archived
4484:Archived
4454:Archived
4421:Archived
4378:Archived
4339:Archived
4305:Archived
4272:Archived
4246:Archived
4213:Archived
4177:Archived
4149:13 March
4115:cite web
4105:13 March
4078:13 March
4072:Archived
4037:Archived
4004:Archived
3971:12 April
3965:Archived
3935:Archived
3914:6 August
3882:16776017
3847:Archived
3816:Archived
3783:Archived
3643:Archived
3625:24670875
3593:: 4483.
3560:Archived
3508:Archived
3479:Archived
3461:22522925
3355:20629632
3347:10742152
3312:12908564
3212:12610629
3169:14528282
3147:Oncogene
3126:20 April
3120:Archived
3097:34778864
3089:17392727
3052:19 April
3046:Archived
3013:11329054
2967:Archived
2946:22065936
2905:27190873
2897:21633346
2862:11870163
2816:Archived
2784:Archived
2766:17589560
2739:25832514
2731:16495393
2690:25624974
2682:16236737
2629:16236738
2570:Archived
2544:40236173
2536:14750129
2490:15611642
2444:11156524
2422:Oncogene
2403:14613984
2376:14613027
2352:Swain SM
2350:Tan AR,
2337:22513938
2288:17611206
2250:22513938
2196:25032250
2187:10845883
2136:Archived
2132:24919460
2068:(2023).
1973:Archived
1937:Archived
1903:Archived
1864:Archived
1834:Archived
1798:Archived
1794:DailyMed
1771:6 August
1765:Archived
1713:Archived
1654:Archived
1621:Archived
1591:2 August
1585:Archived
1546:Archived
1542:DailyMed
1516:Archived
1481:Archived
1477:DailyMed
1432:Archived
1428:DailyMed
1399:Archived
1395:DailyMed
1366:Archived
1362:DailyMed
1333:Archived
1329:DailyMed
1300:Archived
916:dimerize
912:mitogens
857:HER2/neu
803:require
745:diarrhea
598:(verify)
413:DrugBank
402:46507516
239:ATC code
185:category
167:DailyMed
103:HER2/neu
10129:Ephrins
9833:DS-6051
9732:DS-6051
9637:LM22A-4
9627:DMAQ-B1
9582:7,8-DHF
9562:3,7-DHF
9531:RBM-004
9476:GBR-900
9407:DS-6051
9377:VM-902A
8847:RBM-004
8544:OSl-906
8504:Insulin
8383:MK-2461
8328:AMG-458
7465:Axokine
5809:bcr-abl
5170:myeloid
4832:2722050
4645:29 July
4460:28 July
4427:28 July
4345:28 July
4311:28 July
4252:28 July
3890:7873442
3761:3466178
3729:Bibcode
3702:4357655
3694:6095109
3674:Bibcode
3649:16 June
3616:3967150
3595:Bibcode
3514:16 June
3485:24 June
3452:3440846
3431:Bibcode
3404:9497915
3271:4357211
3263:6504162
3243:Bibcode
3220:2311471
3192:Bibcode
3021:6010551
2937:3209542
2637:9534884
2328:6718210
2241:6718210
2123:6464904
1979:28 July
1840:28 July
1804:28 July
1627:28 July
1057:History
1032:Ventana
963:mitosis
952:cofilin
805:cleanup
533:Formula
422:DB00072
387:PubChem
313:Rx-only
310:WARNING
294::
255:)
249: (
247:L01FD01
198: D
169::
10280:Portal
10099:Others
9793:BNN-20
9682:ANA-12
9607:BNN-20
9327:DHEA-S
9312:BNN-27
9307:BNN-20
8746:DHEA-S
8731:BNN-27
8726:BNN-20
8642:Others
7847:Epigen
7525:Epigen
7300:WHO-EM
5056:VEGF-A
4866:
4839:
4829:
4767:
4580:29 May
4550:29 May
4520:29 May
4490:29 May
3998:
3888:
3880:
3822:30 May
3789:30 May
3759:
3752:387088
3749:
3700:
3692:
3666:Nature
3623:
3613:
3459:
3449:
3423:Nature
3402:
3395:379641
3392:
3353:
3345:
3310:
3300:
3269:
3261:
3235:Nature
3218:
3210:
3184:Nature
3167:
3095:
3087:
3019:
3011:
2944:
2934:
2903:
2895:
2860:
2764:
2737:
2729:
2688:
2680:
2635:
2627:
2542:
2534:
2488:
2442:
2401:
2374:
2335:
2325:
2286:
2248:
2238:
2194:
2184:
2145:9 June
2130:
2120:
2001:
1267:, and
1244:2023.
1139:Emcure
984:CDKN1B
948:N-WASP
887:, and
741:nausea
718:- and
653:, and
489:ChEMBL
478:D03257
389:
307:
296:℞-only
282:
165:
98:Target
88:(from
81:Source
10248:(see
10198:(see
10169:(see
10116:(see
9848:K252a
9747:K252a
9422:K252a
9362:FX007
9122:GFRα4
9091:GFRα3
9060:GFRα2
9024:GFRα1
8652:IGFBP
8605:IGF-2
8584:R1507
8472:IGF-1
8378:K252a
8198:FGFR4
8117:FGFR3
7984:FGFR2
7901:FGFR1
6646:Mouse
6385:Human
6377:Tumor
6050:ANXA2
6022:Other
5920:MAP2K
5791:(ALK)
5776:c-MET
5628:VEGFR
5563:PDGFR
5559:C-kit
5190:Other
5039:EpCAM
4700:(FDA)
4450:(EMA)
4417:(EMA)
4374:(FDA)
4370:U.S.
4335:(FDA)
4331:U.S.
4301:(EMA)
4242:(EMA)
4173:(FDA)
4169:U.S.
4070:(4).
3886:S2CID
3698:S2CID
3351:S2CID
3267:S2CID
3216:S2CID
3093:S2CID
3017:S2CID
2970:(PDF)
2963:(PDF)
2901:S2CID
2819:(PDF)
2812:(PDF)
2790:2 May
2735:S2CID
2686:S2CID
2633:S2CID
2576:5 May
2566:(FDA)
2562:U.S.
2540:S2CID
2139:(PDF)
2098:(PDF)
2030:(FDA)
2026:U.S.
1969:(EMA)
1933:(FDA)
1929:U.S.
1830:(EMA)
1617:(EMA)
1104:Mylan
861:ErbB2
547:10012
90:mouse
10250:here
10200:here
10171:here
10118:here
9913:VEGF
9887:VEGF
9803:NT-3
9798:DHEA
9782:TrkC
9702:DHEA
9672:TDP6
9652:NT-4
9647:NT-3
9632:HIOC
9602:BDNF
9551:TrkB
9322:DHEA
9291:TrkA
9271:here
9269:See
9262:TGFβ
8867:PDGF
8761:NT-4
8756:NT-3
8741:DHEA
8721:BDNF
7470:CNTF
7454:CNTF
6165:KRAS
6070:IL-2
6052:and
6034:VEGF
5951:EML4
5610:FLT3
5561:and
5449:ErbB
5175:CD33
5157:CD52
5147:CD30
5107:CD20
4975:ErbB
4880:2020
4864:PMID
4837:PMID
4798:2019
4765:ISBN
4742:2023
4712:2019
4696:U.S.
4678:2023
4647:2024
4615:2023
4582:2022
4552:2022
4522:2022
4492:2022
4462:2020
4429:2020
4386:2019
4347:2020
4313:2020
4280:2018
4254:2020
4221:2017
4185:2019
4151:2023
4121:link
4107:2023
4080:2023
4045:2015
4032:Time
4012:2023
3996:ISSN
3973:2012
3943:2013
3916:2009
3878:PMID
3824:2016
3791:2016
3757:PMID
3690:PMID
3651:2013
3621:PMID
3568:2013
3542:2013
3516:2013
3487:2008
3457:PMID
3400:PMID
3343:PMID
3308:PMID
3298:ISBN
3259:PMID
3208:PMID
3165:PMID
3128:2011
3085:PMID
3054:2011
3009:PMID
2978:2013
2942:PMID
2893:PMID
2858:PMID
2827:2013
2792:2017
2762:PMID
2727:PMID
2678:PMID
2625:PMID
2578:2021
2532:PMID
2486:PMID
2440:PMID
2399:PMID
2372:PMID
2333:PMID
2311:2012
2284:PMID
2246:PMID
2224:2012
2192:PMID
2170:2014
2147:2018
2128:PMID
2106:2014
2042:2019
1999:ISBN
1981:2020
1945:2020
1911:2016
1872:2023
1842:2020
1806:2020
1773:2022
1721:2023
1691:2023
1662:2019
1629:2020
1593:2022
1554:2023
1524:2023
1489:2023
1440:2023
1407:2023
1374:2023
1341:2023
1308:2016
1146:US$
1093:UCLA
1065:and
1025:HER2
967:cdk2
944:MAPK
940:EGFR
928:MAPK
920:PI3K
901:EGFs
889:HER4
885:HER3
881:HER1
871:and
859:and
852:HER2
849:The
743:and
638:and
622:and
559:2013
553:1726
541:6470
469:KEGG
449:UNII
440:none
333:data
135:AHFS
71:Type
9667:R13
9337:NGF
9282:Trk
8751:NGF
8463:IGF
8323:AM7
8214:FGF
8133:FGF
8034:),
8032:KGF
8000:FGF
7917:FGF
7892:FGF
7494:EGF
5955:ALK
5855:Src
5730:RET
5704:ALK
5154:),
5144:),
5104:),
5089:CD3
4945:L01
4827:PMC
4819:doi
3870:doi
3747:PMC
3737:doi
3682:doi
3670:312
3611:PMC
3603:doi
3447:PMC
3439:doi
3427:486
3390:PMC
3382:doi
3335:doi
3290:doi
3251:doi
3239:312
3200:doi
3188:421
3155:doi
3077:doi
3001:doi
2932:PMC
2885:doi
2850:doi
2758:120
2717:doi
2713:354
2668:hdl
2660:doi
2656:353
2615:doi
2611:353
2522:doi
2476:doi
2430:doi
2364:doi
2323:PMC
2315:doi
2276:doi
2272:357
2236:PMC
2228:doi
2182:PMC
2174:doi
2118:PMC
2110:doi
2074:hdl
1684:FDA
1071:neu
1021:PCR
924:Akt
905:HER
873:p27
869:p21
758:or
581:.86
579:531
577:145
392:SID
252:WHO
10306::
10161:B3
10159:,
10157:B2
10155:,
10153:B1
10151:,
10149:A5
10147:,
10145:A4
10143:,
10141:A3
10139:,
10137:A2
10135:,
10133:A1
9927:,
9923:,
9919:,
9662:R7
9478:;
8897:,
8893:,
8889:,
8678:,
8674:,
8670:,
8666:,
8662:,
8658:,
8615::
8482::
8291::
8242:19
8240:,
8236:,
8232:,
8228:,
8224:,
8220:,
8161:23
8159:,
8157:18
8155:,
8151:,
8147:,
8143:,
8139:,
8056:22
8054:,
8052:18
8050:,
8048:17
8046:,
8042:,
8038:,
8026:,
8022:,
8018:,
8014:,
8010:,
8006:,
7953:20
7951:,
7947:,
7943:,
7939:,
7935:,
7931:,
7927:,
7923:,
7875:,
7871:,
7867:,
7863:,
7798:,
7794:,
7700::
7508::
7313::
7205:/
5787:,
5757:,
5745:,
5617:,
5556::
5451::
5172::
5100:,
5096:,
5086::
5004:,
4977::
4954:CI
4939:/
4897:.
4858:.
4835:.
4825:.
4815:16
4813:.
4809:.
4788:.
4782:.
4728:.
4694:.
4664:.
4637:.
4624:^
4601:.
4590:^
4568:.
4538:.
4508:.
4478:.
4445:.
4412:.
4368:.
4355:^
4329:.
4296:.
4270:.
4237:.
4211:.
4167:.
4137:.
4117:}}
4113:{{
4097:.
4068:27
4062:.
4035:.
4029:.
4002:.
3994:.
3990:.
3959:.
3933:.
3884:.
3876:.
3866:36
3864:.
3845:.
3841:.
3814:.
3808:.
3777:.
3755:.
3745:.
3735:.
3725:83
3723:.
3719:.
3696:.
3688:.
3680:.
3668:.
3619:.
3609:.
3601:.
3589:.
3585:.
3495:^
3477:.
3455:.
3445:.
3437:.
3425:.
3421:.
3398:.
3388:.
3378:50
3376:.
3372:.
3349:.
3341:.
3329:.
3306:.
3296:.
3265:.
3257:.
3249:.
3237:.
3214:.
3206:.
3198:.
3186:.
3163:.
3151:22
3149:.
3145:.
3118:.
3114:.
3091:.
3083:.
3073:81
3071:.
3044:.
3040:.
3029:^
3015:.
3007:.
2995:.
2965:.
2940:.
2928:16
2926:.
2922:.
2899:.
2891:.
2881:90
2879:.
2856:.
2846:20
2844:.
2800:^
2756:.
2733:.
2725:.
2711:.
2707:.
2684:.
2676:.
2666:.
2654:.
2631:.
2623:.
2609:.
2605:.
2560:.
2538:.
2530:.
2518:57
2516:.
2512:.
2498:^
2484:.
2470:.
2466:.
2452:^
2438:.
2426:19
2424:.
2420:.
2393:.
2370:.
2360:30
2358:.
2331:.
2321:.
2309:.
2305:.
2282:.
2270:.
2258:^
2244:.
2234:.
2222:.
2218:.
2204:^
2190:.
2180:.
2168:.
2164:.
2134:.
2126:.
2116:.
2104:.
2100:.
2024:.
2013:^
1964:.
1953:^
1927:.
1880:^
1858:.
1825:.
1814:^
1792:.
1781:^
1759:.
1737:.
1707:.
1682:.
1678:.
1652:.
1648:.
1637:^
1612:.
1601:^
1579:.
1562:^
1540:.
1510:.
1497:^
1475:.
1464:^
1448:^
1426:.
1415:^
1393:.
1382:^
1360:.
1349:^
1327:.
1316:^
1298:.
1294:.
1283:^
1271:.
875:.
747:.
672:.
649:,
642:.
565:42
318:EU
303:US
291:CA
284:S4
278:AU
218:,
194:AU
162:US
10282::
10194:/
10163:)
10131:(
9931:)
9925:C
9921:B
9917:A
9915:(
9464:)
8901:)
8899:D
8895:C
8891:B
8887:A
8885:(
8682:)
8680:7
8676:6
8672:5
8668:4
8664:3
8660:2
8656:1
8654:(
8244:)
8238:9
8234:8
8230:6
8226:4
8218:1
8216:(
8163:)
8153:9
8149:8
8145:4
8137:1
8135:(
8058:)
8040:9
8036:8
8030:(
8028:7
8024:6
8020:5
8016:4
8012:3
8004:1
8002:(
7955:)
7945:8
7941:6
7937:5
7933:4
7929:3
7921:1
7919:(
7879:)
7873:4
7869:3
7865:2
7861:1
7859:(
7802:)
7796:2
7792:1
7790:(
7357:e
7350:t
7343:v
7209:)
7201:(
6413:)
6409:(
6360:e
6353:t
6346:v
6077:)
6073:(
6061:)
6057:(
6041:)
6037:(
5953:-
5867:)
5858:(
5613:(
5605:)
5566:(
5521:)
5457:(
5208:)
5204:(
5182:)
5178:(
5164:)
5160:(
5150:(
5110:(
5092:(
5074:/
5063:)
5059:(
5051:)
5042:(
5023:)
5012:)
5008:(
5000:(
4992:)
4983:(
4947:)
4943:(
4929:e
4922:t
4915:v
4882:.
4843:.
4821::
4800:.
4773:.
4744:.
4714:.
4680:.
4649:.
4617:.
4584:.
4554:.
4524:.
4494:.
4464:.
4431:.
4399:.
4388:.
4349:.
4315:.
4282:.
4256:.
4223:.
4198:.
4187:.
4153:.
4123:)
4109:.
4082:.
4047:.
4014:.
3975:.
3945:.
3918:.
3892:.
3872::
3826:.
3793:.
3763:.
3739::
3731::
3704:.
3684::
3676::
3653:.
3627:.
3605::
3597::
3591:4
3570:.
3544:.
3518:.
3489:.
3463:.
3441::
3433::
3406:.
3384::
3357:.
3337::
3331:6
3314:.
3292::
3273:.
3253::
3245::
3222:.
3202::
3194::
3171:.
3157::
3130:.
3099:.
3079::
3056:.
3023:.
3003::
2997:7
2980:.
2948:.
2907:.
2887::
2864:.
2852::
2829:.
2794:.
2768:.
2741:.
2719::
2692:.
2670::
2662::
2639:.
2617::
2591:.
2580:.
2546:.
2524::
2492:.
2478::
2472:4
2446:.
2432::
2405:.
2395:9
2378:.
2366::
2339:.
2317::
2290:.
2278::
2252:.
2230::
2198:.
2176::
2149:.
2112::
2076::
2055:.
2044:.
2007:.
1983:.
1947:.
1913:.
1874:.
1844:.
1808:.
1775:.
1723:.
1693:.
1664:.
1631:.
1595:.
1556:.
1526:.
1491:.
1442:.
1409:.
1376:.
1343:.
1310:.
922:/
840:)
834:(
829:)
825:(
562:S
556:O
550:N
544:H
538:C
320::
305::
280::
196::
137:/
92:)
34:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
